Document:

English translation of Form of Real Property Sale and Purchase Agreement

 EXHIBIT 4.10 

Form of Real Estate Sale and Purchase Agreement 
  

							
	Seller:	  	 Beijing Suo Tu Shi Ji Investment Management Co., Ltd.

				
	Legal person:	  	  
	  	Organization code:	  	  

		
	Address:	  	  

				
	Post code:	  	  
	  	Telephone:	  	  

				
	Agent:	  	  
	  	Nationality:	  	  

		
	ID No.:	  	  

		
	Address:	  	  

				
	Post code:	  	  
	  	Telephone:	  	  

		
	Buyer:	  	 TAL Education & Technology (Beijing) Co., Ltd.

				
	Legal person:	  	  
	  	Organization code:	  	  

		
	Address:	  	  

				
	Post code:	  	  
	  	Telephone:	  	  

				
	Agent:	  	  
	  	Nationality:	  	  

		
	ID No.:	  	  

		
	Address:	  	  

				
	Post code:	  	  
	  	Telephone:	  	  

 In accordance with the Contract Law of the People’s Republic of China, the Law of the People’s
Republic of China on the Administration of Urban Real Estate, and the Law of the People’s Republic of China on the Transfer of Urban Real Estate, and on the basis of equal, voluntary and fair negotiation, the Seller and the Buyer have come to
the following agreements regarding the sale and purchase of pre-owned real estate: 
 Clause 1: Basic information on the Real Estate

  

	(1)	The real estate to be sold by the Seller (hereinafter referred to as the Real Estate) is part of a multi-storied building located at
        . The building has     16     floors, including     13     above the ground and
    3     below. 

 The Real Estate is on the
     floor with a super built-up area of square meters. 
  

	(2)	The Real Estate is intended for:     business and commercial use    . 

Details on the auxiliary facilities/fixtures, renovations and trappings and list of relevant items are included in Appendix I. 

Clause 2: Title of the Real Estate 
  

	(1)	The title certificate number of the Real Estate is:         , co-ownership certificate number is:
    ×    , and the certificate is issued by:
                                         
       . 

 Opinion of the co-owner of the Real Estate is included in
Appendix II. 
  

	(2)	Land use status 

 The right of
use for the state-owned land on which the Real Estate is located was acquired for a payment. The land use right certificate is numbered:     ×    , and issued by:
    ×    . 
  

	(3)	The nature of the Real Estate:     marketable    . 

 

	(4)	The status of the Real Estate as collateral:     not used as collateral    . 

 

	(5)	The leasing status of the Real Estate:     not leased out by the Seller    . 

Detailed information on the title of the Real Estate and its use as collateral and its leasing status can be found under Appendix III.

 Clause 3 
 The Seller and the
Buyer agree to adopt the 1st option(s) to complete the transaction. 
  

	1.	The Seller and the Buyer engage a real estate brokerage firm (i.e.:
                                         
       ) as the mediator to conclude the deal, and the real estate agent is:
                                         
    

  

	2.	The Seller engages a real estate brokerage firm (i.e.:     ×    ) to conclude the deal, and the real estate
agent is:     ×    . 

  

	3.	The Buyer engages a real estate brokerage firm (i.e.:     ×    ) to complete the transaction, and the real
estate agent is:     ×    . 

 The Seller Brokerage Agreement and the Buyer Brokerage Agreement can be found in Appendix
IV. 
 Clause 4: Sold price, payment arrangement and means of fund transfer 

 

	(I)	As agreed between the Buyer and the Seller, the Real Estate is sold at RMB          (amount in number) or RMB
         (amount in words), including the Buyer’s own funds of RMB          (amount in number) or RMB
         (amount in words). 

 Where the prices of the auxiliary
facilities/fixtures and renovation/trappings are separately agreed, the specifics are included in Appendix I. 
  

	(II)	The Buyer will make the payment using the     2nd     option, with detailed payment and timetable arrangements set out in
Appendix V. 

  

	 	1.	Settlement through arrangement agreed between the Buyer and the Seller, and their Statement on Discretionary Transfer of Funds for Settlement of Pre-owned Real Estate
is included in Appendix VI. 

  

	 	2.	Settlement through transfer of the Buyer’s own funds from the controlled account of     Haidian District Housing Authority of
Beijing     for settlement of pre-owned real estate properties with the buyer’s own funds, and the Agreement on Transfer of Buyer’s Own Funds for Settlement of Pre-owned Real Estate Transaction between the Buyer and
the Seller is included in Appendix VI. 

  

	 	(1)	For transfer of funds through the controlled account, the Buyer shall deposit the purchase consideration of RMB         
(amount in number) or RMB          (amount in words) into the controlled account of Haidian District Housing Authority of Beijing designated for settlement of pre-owned real estate properties with the
buyer’s own funds, and upon the Buyer’s obtaining the real estate title certificate, the funds in the controlled account shall be transferred in a one-off exercise through the pre-owned real estate transaction platform to the Seller’s
receiving account set out by the Buyer and the Seller in their Agreement on Transfer of Buyer’s Own Funds for Settlement of Pre-owned Real Estate Transaction. 

 

	(III)	Agreement concerning loans 

 The
Buyer shall not apply for a mortgage loan. 
 Clause V: Commitment with respect to the title and conditions of the Real Estate

 The Seller shall warrant that the Real Estate is free of title disputes and shall assume relevant liabilities for failure to complete
title registration or debtor/creditor disputes due to causes attributable to the Seller. 
 The Seller shall warrant that it has provided a true
statement with respect to the title, auxiliary facilities/fixtures, renovations/trappings of the Real Estate and their relationships. The auxiliary facilities/fixtures and the renovations/trappings of the Real Estate as set out in Appendix I shall
be sold together with the Real Estate to the Buyer. The Buyer has adequate understanding of the conditions of the Real Estate sold by the Seller, and buys the Real Estate on its own volition. 
 The Seller shall maintain the good conditions of all auxiliary facilities/fixtures and renovations/trappings of the Real Estate as included in Appendix I from the date of signing this contract until the
date the check-up and acceptance are completed. 
 The [property management expenses], [heating], [water], [electricity], [gas], [cable TV],
[telecom], and [××] expenses in the amount of:     ×     incurred before the date of delivery of the Real Estate shall 

 
be borne by the Seller, while such expenses incurred on and after the date of delivery shall be borne by the Buyer. The Seller agrees to transfer the balance of its contribution of special
maintenance funds (public maintenance funds) to the Buyer. 
 Clause VI: Delivery of the Real Estate 

The Seller shall deliver the Real Estate to the Buyer     before 10 December 2011    . Upon delivery
of the Real Estate, the following     ×    ,     ×    , and/or     ×     procedures:

  

	1.	The Seller and the Buyer check together the auxiliary facilities/fixtures, renovations/trappings and items of the Real Estate as included in the checklist, record the
readings of the water, electricity and gas meters, and complete the handing over of items listed in Appendix I from Seller to the Buyer. 

  

	2.	The Seller and the Buyers sign off the checklist of auxiliary facilities/fixtures, renovations/trappings and relevant items of the Real Estate.

  

	3.	The Seller to hand over the keys of the Real Estate to the Buyer. 

 Clause VII: Liabilities for breach of contract 
  

	(I)	Liabilities for delay in delivery of the Real Estate 

 If the Seller fails to deliver the Real Estate to the Buyer as agreed under Clause VI as a result other than force majeure, the two parties agree to follow option 1 as described below. 

 

	 	1.	Depending on the number of days of delay, either (1) or (2) shall apply (and the two are not on a cumulative basis). 

 

	 	(1)	For delay of less than     30     days, the Seller shall pay damages to the Buyer in the amount of
    three     ten-thousandth of the purchase consideration paid by the Buyer for each of the days of delay from the day following the last day for delivery as agreed under Clause VI to the actual
delivery date and within     30     days from the actual delivery date, and the Contract shall continue in full force and effect; 

 

	 	(2)	If the delay exceeds     30     days (the 30th day being the same day under paragraph (1) above), the Buyer is
entitled to rescind the purchase. If the Buyer elects to do so, the Seller shall return all amount already paid by the Buyer within     30     days from the date the cancellation notice is delivered,
and pay damages to the Buyer in the amount of     three     % of the total amount already paid by the Buyer. 

 

	 	2.	    ×                      
                                         
                                         
                                         
                                         
      . 

  

	(II)	Liabilities for delay in payment of purchase consideration 

 Should the Buyer fail to make payments by the timetable as agreed under Appendix IV, the option     1     below shall apply. 

 

	 	1.	Depending on the number of days of delay, either (1) or (2) shall apply (and the two are not on a cumulative basis). 

 

	 	(1)	 For delay of less than     30     days, the Buyer shall pay damages to the Seller in the amount of
    three     ten thousands of the overdue amount payable for each of the day from the day following the last payment day agreed between the two parties to the

	 	
actual payment date and within     30     days from the date of actual payment of the outstanding amount, and the Contract shall continue in full
force and effect; 

  

	 	(2)	If the delay exceeds     30     days (the 30th day being the same day under paragraph (1) above, the Seller is
entitled to rescind the sale. If the Seller elects to do so, the Buyer shall pay damages to the Seller in the amount of     10     % of the total purchase consideration within
    30     days from the date the cancellation notice is delivered, and the Seller shall return all amount already paid to the Buyer. 

 

	 	2.	    ×                      
                                         
                                         
                                         
                                         
      . 

 Clause VIII 
 If the Seller has sold the Real Estate to a third party so that the Buyer is unable to obtain the title to the Real Estate, the Buyer is entitled to rescind the purchase, and the Seller shall return all
amount paid by the Buyer within     30     days from the date the cancellation notice is delivered, pay interests to the Buyer at the interest rate of
    ×    , and pay damages to the Buyer at twice the cumulative total of amount paid by the Buyer. 
 Clause IX: Taxes and charges 
 During the performance of the Contract, the Buyer and Seller
shall comply with relevant regulations of the state and Beijing municipality in paying taxes and charges, and the taxes and charges to be borne by the two parties are set out under Appendix VII. Should failure on either party to pay taxes and
charges as required by laws and regulations make it impossible for the transaction to proceed, it shall pay damages to the other party at     five     % of the purchase consideration. 

If in the course of performing the Contract, new taxes and/or charges need to be paid due to policy changes, the taxes and/or charges shall be paid by
the party specified by the policy to pay such taxes/charges; if no party has been specified, the Buyer shall be responsible for the payment. 

Clause X: Title transfer registration 
  

	(I)	The two parties agree that the two parties shall, within     180     days from the signing of the Contract, apply
together to the housing title registration authorities to complete the procedures for title transfer registration. 

  

	(II)	If the Buyer cannot obtain the title certificate within     360 days from the date of signing the Contract     (agreed
time or conditions), the two parties agree to proceed as follows. 

  

	 	1.	If it is due to the Seller, the Buyer is entitled to cancel the purchase. If the Buyer elects to do so, the Seller shall return all amount paid by the Buyer within
    30     days from the date the cancellation notice is delivered, and pay interests to the Buyer at the     deposit interest rate for the same
period    . If the Buyer does not elect to cancel the purchase, the Seller shall pay damages to the Buyer at     one     ten-thousandth of all the amount paid by the Buyer for
each day from the day following the last day of the period set for the Buyer to obtain the title certificate to the actual day when the Buyer obtains the title certificate and within     30     days
from the day when the Buyer actually obtains the title certificate. 

  

	 	2.	    ×                      
                                         
                                         
                                         
                                         
       . 

  

	(III)	 The Seller shall, within     30     days upon transfer of the title of the Real Estate, complete the
procedures for household registration changes at the local household authorities. If due to the Seller, the Seller fails to complete the household registration changes relating to the Real Estate,

 
the Seller shall pay damages to the Buyer in the amount of RMB     ×    ; if the Seller has not completed the household registration
changes after     ×     days, the Seller shall pay damages to the Buyer per diem at          ten-thousandth of the total amount paid by the
Buyer from the day following the agreed date. 

    ×                 
                                         
                                         
                                         
                                         
           . 
 Clause XI: Force majeure 

If due to force majeure the Contract cannot be carried out as agreed, the liabilities as a result shall be partially or fully exempted depending on the
severity of the force majeure. However, the party who cannot carry out the Contract as agreed due to the force majeure shall notify the other party in a timely manner, and shall provide proof of the force majeure to the other party within
    30     days upon the ending of the force majeure event. 
 The above risks/liabilities of the
Real Estate are transferred to the Buyer on the date of [transfer of title] [transfer and possession ü]. 
 Clause XII: Resolution of disputes 
 Any disputes under the Contract shall be settled
through negotiation, and if negotiation cannot resolve the disputes, the two parties agree to adopt option     (I)     for resolution of the disputes: 

 

	(1)	File an action to the People’s Court of the place where the Real Estate is located; 

 

	(2)	Submit the case to
                             (arbitration commission) for arbitration. 

Clause XIII 
 The Contract will come into
effect on the date of signing of the Contract by the two parties. The two parties may, as appropriate in the circumstances, modify or amend the Contract with respect to terms or provisions that are not agreed, not clearly defined or irrelevant
through written supplementary agreements (Appendix VIII). The termination of the Contract, if required, shall be done in writing. The appendices and the supplementary agreements to the Contract shall have the same legal force as the Contract.

 Clause XIV 
 The Contract and
appendices, totalling              pages, are signed in     six     counterparts, which all have the same legal force, including
    three     counterparts for the Seller,     one     counterpart for the Buyer,     one     counterpart
for         Haidian District Housing Authority of Beijing    , and     one     counterpart for     Haidian
District Local Tax Bureau of Beijing    . For the purpose of transfer registration, the two parties shall submit a copy of the master contract to the real estate title registration authority, and Appendices II and III shall
also need to be submitted if they contain any specific agreements between the two parties. 

							
	Seller (signature/stamp)	 		 	Buyer (signature/stamp)	 	
				
	[Legal representative]:	 		 	[Legal representative]:	 	
				
	 [Agent]
 (signature/stamp)
:
	 		 	 [Agent]
 (signature/stamp)
:
	 	
				
	Date of signing:	 	     /    /2011
 (dd/mm/yy)
	 	Date of signing:	 	     /    /2011
 (dd/mm/yy)

				
	Place of signing:	 	Beijing	 	Place of signing:	 	Beijing

 Schedule A 
 All the offices we purchased use this form of real estate sale and purchase agreement (“Form Agreement”) therefore, only the Form Agreement is filed with the SEC. Below is a list of material
differences between other executed real estate sale and purchase agreements and this Form Agreement. 
  

											
	 Room No.
	 	 Construction

Area
	 	 Total Contract

Price
	 	 Room No.
	 	 Construction

Area
	 	 Total Contract

Price

	 1201
	 	187.77	 	10,270,809	 	1601	 	187.77	 	10,149,855
	 1202
	 	85.44	 	4,361,951	 	1602	 	85.44	 	4,310,523
	 1203
	 	85.44	 	4,439,791	 	1603	 	85.44	 	4,387,460
	 1205
	 	85.44	 	4,517,712	 	1605	 	85.44	 	4,464,479
	 1206
	 	85.44	 	4,595,633	 	1606	 	85.44	 	4,541,416
	 1207
	 	85.44	 	4,673,472	 	1607	 	85.44	 	4,618,435
	 1208
	 	85.44	 	4,673,472	 	1608	 	85.44	 	4,618,435
	 1209
	 	85.44	 	4,595,633	 	1609	 	85.44	 	4,541,416
	 1210
	 	85.44	 	4,517,712	 	1610	 	85.44	 	4,464,479
	 1211
	 	85.44	 	4,439,791	 	1611	 	85.44	 	4,387,460
	 1212
	 	85.44	 	4,361,951	 	1612	 	85.44	 	4,310,523
	 1213
	 	187.77	 	10,270,809	 	1613	 	187.77	 	10,149,855
	 1215
	 	67.59	 	3,265,797	 	1615	 	67.59	 	3,227,320
	 1216
	 	187.77	 	9,586,185	 	1616	 	187.77	 	9,473,162
	 1217
	 	85.44	 	4,050,348	 	1617	 	85.44	 	4,002,611
	 1218
	 	85.44	 	4,128,270	 	1618	 	85.44	 	4,079,630
	 1219
	 	85.44	 	4,206,108	 	1619	 	85.44	 	4,156,567
	 1220
	 	85.44	 	4,284,030	 	1620	 	85.44	 	4,233,586
	 1221
	 	85.44	 	4,361,951	 	1621	 	85.44	 	4,310,523
	 1222
	 	85.44	 	4,361,951	 	1622	 	85.44	 	4,310,523
	 1223
	 	85.44	 	4,284,030	 	1623	 	85.44	 	4,233,586
	 1225
	 	85.44	 	4,206,108	 	1625	 	85.44	 	4,156,567
	 1226
	 	85.44	 	4,128,270	 	1626	 	85.44	 	4,079,630
	 1227
	 	85.44	 	4,050,348	 	1627	 	85.44	 	4,002,611
	 1228
	 	187.77	 	9,586,185	 	1628	 	187.77	 	9,473,162
	 	 	 	 	 	 	 	 	 	 	 
	 Total

(12 F)
	 		 	130,218,318	 	 Total
 (16 F)
	 		 	128,683,817
	 	 	 	 	 	 	 	 	 	 	 
	 1501
	 	187.77	 	10,060,807	 	 Total
 (12/15/16 F)
	 	7582.41	 	386,457,448
		 		 		 	 	 	 	 	 
	 1502
	 	85.44	 	4,272,711	 		 		 	
	 1503
	 	85.44	 	4,348,992	 		 		 	
	 1505
	 	85.44	 	4,425,355	 		 		 	
	 1506
	 	85.44	 	4,501,635	 		 		 	
	 1507
	 	85.44	 	4,577,916	 		 		 	
	 1508
	 	85.44	 	4,577,916	 		 		 	
	 1509
	 	85.44	 	4,501,635	 		 		 	
	 1510
	 	85.44	 	4,425,355	 		 		 	
	 1511
	 	85.44	 	4,348,992	 		 		 	
	 1512
	 	85.44	 	4,272,711	 		 		 	
	 1513
	 	187.77	 	10,060,807	 		 		 	
	 1515
	 	67.59	 	3,199,029	 		 		 	
	 1516
	 	187.77	 	9,390,062	 		 		 	
	 1517
	 	85.44	 	3,967,506	 		 		 	
	 1518
	 	85.44	 	4,043,868	 		 		 	
	 1519
	 	85.44	 	4,120,149	 		 		 	
	 1520
	 	85.44	 	4,196,430	 		 		 	
	 1521
	 	85.44	 	4,272,711	 		 		 	
	 1522
	 	85.44	 	4,272,711	 		 		 	
	 1523
	 	85.44	 	4,196,430	 		 		 	
	 1525
	 	85.44	 	4,120,149	 		 		 	
	 1526
	 	85.44	 	4,043,868	 		 		 	
	 1527
	 	85.44	 	3,967,506	 		 		 	
	 1528
	 	187.77	 	9,390,062	 		 		 	
	 	 	 	 	 	 		 		 	
	 Total

(15 F)
	 		 	127,555, 313Binding Commitment to Lend

 [***] Indicates confidential material that has been omitted pursuant to a Confidential Treatment
Request filed with the Securities and Exchange Commission. A complete copy of this agreement has been separately filed with the Securities and Exchange Commission. 
 Exhibit 10.32 
 BAY CITY
CAPITAL FUND IV, L.P. 
 750 Battery Street, Suite 400 

San Francisco, CA 94111 
 CONFIDENTIAL  
 June 22, 2011 

Poniard Pharmaceuticals, Inc. 
 750 Battery
Street, Suite 330 
 San Francisco, CA 94111 
 Attn: Ronald A. Martell 
  

	Re:	Binding Commitment to Lend 

 Ladies and
Gentlemen: 
 Reference is made to the Agreement and Plan of Merger and Reorganization, dated as of the date hereof (the
“Merger Agreement”), by and among Poniard Pharmaceuticals, Inc., a Washington corporation (the “Company”), FV Acquisition Corp., a Delaware corporation, and Allozyne, Inc., a Delaware corporation (collectively the
“Merger Parties”). 
 This letter, when accepted by the undersigned on behalf of the Company, without modification or
addition, constitutes the commitment of Bay City Capital Fund IV, L.P., a Delaware limited partnership (the “Lender”) to make a loan to the Company on the following terms and conditions: 

1. Subject to (a) the satisfaction (or waiver) of all of the conditions precedent of the Merger Parties pursuant to the Merger Agreement to effect
the Merger (as defined in the Merger Agreement) and immediately prior to the Effective Time (as defined in the Merger Agreement), (b) the satisfaction (or waiver by the Lender) of all of the terms and conditions precedent in the draft Loan and
Security Agreement attached hereto as Exhibit A (the “Loan Agreement”), (c) there not occurring any material adverse effect on the Collateral (as defined in the Loan Agreement) or any portion thereof after the date hereof, and
(d) the payment by the Company of a commitment fee in the amount of $50,000 within three days of the acceptance of this letter by the undersigned, the Lender hereby gives its binding commitment and agrees to execute and deliver to the Company
the Loan Agreement in substantially the form attached hereto as Exhibit A (including all exhibits thereto), against receipt from the Company of the Secured Non-Recourse Promissory Note in substantially the form attached hereto as Exhibit
B, and to loan to the Company upon the terms and subject to the conditions set forth in the Loan Agreement the sum of Two Million Four Hundred Thousand Dollars ($2,400,000) no later than immediately prior to the Effective Time (the
“Loan”). 
 2. This letter (this “Binding Commitment”) will terminate on the earlier to occur of (i) the
date on which the Merger Agreement is terminated in accordance with its terms, or (ii) making of the Loan and the consummation of the transactions contemplated by the Merger Agreement. 

 
Upon termination of this Binding Commitment, the Lender shall not have any further obligations or liabilities hereunder. 
 3. The provisions of this Binding Commitment contain the entire understanding of the Parties with respect to the subject matter hereof and supersede any prior agreements (whether written or oral) between
the Parties with respect to such subject matter. 
 4. This Binding Commitment is intended to be solely for the benefit of the Company and the
Lender and shall not confer any benefits upon, or create any rights in favor of, any person other than the Company and the Lender. No person, other than the parties signatory hereto, is entitled to rely upon this Binding Commitment or any of its
contents in extending, or considering extensions of, any credit to the Company or for any other reason. 
 5. This Binding Commitment shall be
governed by the laws of the State of Washington (without reference to the principles of conflicts of laws). This Binding Commitment may not be amended, modified or waived by any party in any manner adverse to the Company without the prior written
consent of the Company. 
 [SIGNATURE PAGE TO FOLLOW] 

 
			
	Very truly yours,
	
	LENDER:
	
	BAY CITY CAPITAL FUND IV, L.P.
		
	By:	 	Bay City Capital Management IV LLC,
its general partner
		
	By:	 	Bay City Capital LLC, its manager
		
	By:	 	/s/ Carl Goldfischer
	Name:	 	Carl Goldfischer
	Title:	 	Managing Director

  

			
	AGREED AND ACCEPTED:
	
	PONIARD PHARMACEUTICALS, INC.
		
	By:	 	/s/ Ronald A. Martell
	Name:	 	Ronald A. Martell
	Title:	 	CEO

 EXHIBIT A 

LOAN AND SECURITY AGREEMENT 
 THIS LOAN AND SECURITY AGREEMENT (this “Agreement”) is entered into as of             , 2011 (the
“Effective Date”), by and between PONIARD PHARMACEUTICALS, INC., a Washington corporation (the “Borrower”), and BAY CITY CAPITAL FUND IV, L.P., a Delaware limited partnership (the
“Lender”). The Borrower and the Lender are sometimes referred to herein collectively as the “Parties” and individually as a “Party.” 
 RECITALS 
 A. On the terms and subject to the conditions set forth herein,
the Lender has agreed to lend to the Borrower Two Million Four Hundred Thousand Dollars (US$2,400,000). 
 B. The board of
directors of the Borrower has determined that it is in the best interests of the Borrower and its shareholders to borrow Two Million Four Hundred Thousand Dollars (US$2,400,000) from the Lender on the terms and conditions set forth herein.

 AGREEMENT 
 NOW THEREFORE, in consideration of the foregoing, and the representations, warranties and conditions set forth below, the Parties, intending to be legally bound, hereby agree as follows: 

1. Definitions. The following terms shall have the meaning set forth below: 

“AnorMED License Agreement” means the License Agreement dated April 2, 2004 and amended
September 18, 2006 between AnorMed, Inc. and the Borrower. 
 “Baxter Supply
Agreement” means the Commercial Supply Agreement between Baxter Oncology GmbH and the Borrower, executed by the Borrower on November 22, 2008. 
 “Change in Control” means (a) the acquisition of ownership, directly or indirectly, beneficially or of record, by any Person or group (within the meaning of the Securities
Exchange Act of 1934 and the rules of the Securities and Exchange Commission thereunder as in effect on the date hereof) other than pursuant to the Merger Agreement, of equity interests representing more than 51% of the aggregate ordinary voting
power represented by the issued and outstanding equity interests of the Borrower; (b) occupation of a majority of the seats (other than vacant seats) on the board of directors of the Borrower by Persons who were neither (i) nominated by
the board of directors of the Borrower nor (ii) appointed by directors so nominated; or (c) the acquisition of direct or indirect Control of the Borrower by any Person or group; provided that the consummation of the transaction
contemplated by the Merger Agreement shall not be deemed to be a Change in Control for purposes of the Transaction Documents. 
 “Collateral” has the meaning provided in Section 4(a) hereof. 

 “Collateral Assignment Agreement” means each of the
Collateral Assignment of Patents and Collateral Assignment of Trademarks, attached hereto as Exhibits A and B respectively. 
 “Control” means the possession, directly or indirectly, of the power to direct or cause the direction of the management or policies of a Person, whether through the ability to
exercise voting power, by contract or otherwise. 
 “Event of Default” has the meaning
provided in the Note. 
 “Governmental Authority” means the government of the United
States of America, any other nation or any political subdivision thereof, whether state or local, and any agency, authority, instrumentality, regulatory body, court, central bank or other entity exercising executive, legislative, judicial, taxing,
regulatory or administrative powers or functions of or pertaining to government. 
 “Heraeus
Commercial Manufacturing Agreement” means the Commercial Picoplatin Active Pharmaceutical Ingredient Manufacturing Agreement dated March 24, 2008 between W.C. Heraeus GmbH and the Borrower. 

“Heraeus Manufacturing Agreement” means the Picoplatin Active Pharmaceutical Ingredient
Manufacturing Agreement dated July 27, 2006 between W.C. Heraeus GmbH and the Borrower. 

“Intellectual Property” means all (i) Trademarks, Trademark License, Patents, and Patent
License including amendments, renewals, and extensions and other rights to use and all license fees and royalties from the use thereof; (ii) all computer programs and software applications and source codes of the Borrower and all intellectual
property rights therein and all other Proprietary Information of the Borrower, including but not limited to, Trade Secrets; and (iii) all Permits. 
 “Merger Agreement” means the Agreement and Plan of Merger and Reorganization among Poniard Pharmaceuticals, Inc., FV Acquisition Corp. and Allozyne, Inc. dated as of
            , 2011. 
 “Patent
License” means any agreement, whether written or oral, providing for the grant by or to the Borrower of any right to manufacture, use or sell any invention covered by a Patent. 

“Patents” means (a) all letters patent of the United States or any other country and all
reissues and extensions thereof, and (b) all applications for letters patent of the United States or any other country and all divisions, continuations and continuations-in-part thereof. 

“Perfection Certificate” means a certificate in the form of Exhibit C hereto, completed and
supplemented with the schedules contemplated thereby to the reasonable satisfaction of the Lender. 

 “Permits” means all licenses, permits, rights,
orders, variances, franchises or authorizations of or from any Governmental Authority 

“Person” means any natural person, corporation, limited liability company, trust, joint venture,
association, company, partnership, Governmental Authority or other entity. 
 “Picoplatin
Technology” means the active pharmaceutical agent picoplatin, which is being developed for use as a human pharmaceutical for oncology therapy. 
 “Proceeds” means all proceeds, which shall include without limitation (a) whatever is acquired upon the sale, lease, license, exchange, or other disposition of any Collateral,
(b) whatever is collected on, or distributed on account of, any Collateral, (c) rights arising out of any Collateral, (d) claims arising out of the loss or nonconformity of, defects in, or damage to any Collateral, (e) claims and
rights to any proceeds of any insurance, indemnity, warranty or guaranty payable to the Borrower (or the Lender, as assignee, loss payee or an additional insured) with respect to any of the Collateral, (f) claims and rights to payments (in any
form whatsoever) made or due and payable to the Borrower from time to time in connection with any requisition, confiscation, condemnation, seizure or forfeiture of all or any part of the Collateral by any Governmental Authority (or any Person acting
under color of Governmental Authority), and (g) any and all other amounts from time to time paid or payable under or in connection with any of the Collateral 

“Proprietary Information” means all information and know-how worldwide, including, without
limitation, technical data; manufacturing data; research and development data; data relating to compositions, processes and formulations, manufacturing and production know-how and experience; management know-how; training programs; manufacturing,
engineering and other drawings; specifications; performance criteria; operating instructions; maintenance manuals; technology; technical information; software; computer programs; engineering and computer data and databases; design and engineering
specifications; catalogs; promotional literature; financial, business and marketing plans; and inventions and invention disclosures. 
 “Trademark License” means any agreement, written or oral, providing for the grant by or to the Borrower of any right to use any Trademark. 

“Trademarks” means (a) all trademarks, trade names, corporate names, company names, business
names, fictitious business names, trade styles, service marks, logos and other source or business identifiers, and the goodwill associated therewith, now existing or hereafter adopted or acquired, all registrations and recordings thereof, and all
applications in connection therewith, whether in the United States Patent and Trademark Office or in any similar office or agency of the United States, any state thereof or any other country or any political subdivision thereof, or otherwise and
(b) all renewals thereof. 
 “Trade Secrets” means any secretly held existing
engineering and other data, information, production procedures and other know-how relating to the design, manufacture, assembly, installation, use, operation, marketing, sale and servicing of any products or business of a Grantor worldwide whether
written or not written. 

 “UCC” means, unless the context indicates otherwise,
the Uniform Commercial Code, as at any time adopted and in effect in the State of [Washington], specifically including and taking into account all amendments, supplements, revisions and other modifications thereto. 

2. The Note. 
 (a) Issuance of the Note. Subject to the terms of this Agreement, the Lender agrees to deliver to the Borrower at the Closing (as defined below), by check payable to the Borrower or by wire
transfer per the Borrower’s wiring instructions (or any combination thereof), the amount of Two Million Four Hundred Thousand Dollars ($2,400,000) (the “Loan”), against the issuance and delivery by the Borrower of the
Secured Non-Recourse Promissory Note in such amount and in substantially the form attached hereto as Exhibit D (the “Note”). 
 (b) Closing. The closing of the Loan (the “Closing”) shall take place on the Effective Date, at such place as mutually agreed upon by the Borrower and the Lender, or at such
other time and place as the Borrower and the Lender mutually agree (the “Closing Date”). 
 3.
Representations and Warranties of the Borrower. The Borrower represents and warrants to the Lender as follows: 
 (a) Due Incorporation, Qualification. The Borrower (i) is a corporation duly organized and validly existing under the laws of the State of Washington, (ii) has the power and authority to
own, lease and operate its properties and carry on its business as now conducted, and (iii) is duly qualified, licensed to do business and in good standing as a foreign corporation in each jurisdiction where such qualification is required.

 (b) Authority. The execution, delivery and performance by the Borrower of this Agreement, the
Collateral Assignments and the Note (collectively the “Transaction Documents”) to be executed by the Borrower and the consummation of the transactions contemplated thereby (i) are within the corporate power of the
Borrower and (ii) have been duly authorized by all necessary actions on the part of the Borrower. 
 (c)
Enforceability. Each Transaction Document executed by the Borrower has been duly executed and delivered by the Borrower and constitutes a legal, valid and binding obligation of the Borrower, enforceable against the Borrower in accordance with
its terms, except as limited by (i) bankruptcy, insolvency, reorganization, moratorium or other laws of general application relating to or affecting the enforcement of creditors’ rights generally and general principles of equity, and
(ii) as limited by laws relating to the availability of specific performance, injunctive relief or other equitable remedies. 
 (d) Compliance with Other Instruments, Etc. The Borrower will not by virtue of entering into and performing the Transaction Documents and the transactions contemplated thereunder be in violation of
or create any default under, (i) any term of the Restated Articles of Incorporation of the Borrower or its Bylaws, or (ii) any term or provision of any material mortgage, indenture, contract, agreement, instrument, judgment or decree to
which it is a party or by which it or any of its properties is bound, or any order, statute, rule or regulation applicable to the Borrower 

 
or any of its properties. The Transaction Documents will not result in the creation or imposition of any lien on any asset of the Borrower, except the liens created pursuant to the Transaction
Documents. 
 (e) Approvals. Except for the filing of one or more UCC-1 financing statements as
contemplated by the Transaction Documents, no consent, approval, order or authorization of, or registration, declaration or filing with, any governmental authority or other person (including, without limitation, the shareholders of any person) is
required in connection with the execution and delivery of the Transaction Documents executed by the Borrower and the performance and consummation of the transactions contemplated thereby. 

(f) Litigation. Other than actions, suits, legal or administrative proceedings, investigations or claims
(“Actions”) pending or, to the Borrower’s knowledge, threatened against the Borrower in connection with the Merger or the Contemplated Transactions (as such terms are defined in the Merger Agreement), there are no
Actions pending or, to the Borrower’s knowledge, threatened against the Borrower and involving or affecting the Collateral, whether in law or in equity, whether civil or criminal in nature or whether before or by a federal, state, municipal, or
other governmental department, commission, board, bureau, agency, or instrumentality, domestic or foreign. 
 (g)
Title to Collateral; Authority. The Collateral and Lender’s rights with respect to the Collateral are not subject to any setoff, claims, withholdings or other defenses. The Collateral is owned by the Borrower, free from any mortgage,
lien, deed of trust, charge, pledge, security interest or other encumbrance. There is no financing statement (or similar statement or instrument of registration under the law of any jurisdiction) covering or purporting to cover any interest of any
kind of the Borrower in the Collateral. All of the Obligations of Lender will, at the time from and after the execution and delivery of each of the Transaction Documents, be entitled to the benefits of and be secured by each of the Transaction
Documents. The Borrower has full power and authority to grant to the Lender the security interest in such Collateral pursuant hereto and to execute, deliver and perform its obligations in accordance with the terms of this Agreement, without the
consent or approval of any other Person. 
 (h) Perfection and Priority. The security interest of the
Borrower hereunder constitutes a legal, valid and enforceable first priority security interest in all of the Collateral of the Borrower, securing the payment and performance of its obligations under the Transaction Documents. After giving effect to
the Borrower’s actions hereunder, the security interest in and to the Collateral will be perfected to the maximum extent a security interest in the Collateral can be perfected under the UCC of any applicable jurisdiction. 

(i) Filings; Information. All notifications and other actions, including, without limitation, (i) all notices
to and acknowledgments of any Person, (ii) all acknowledgments and agreements respecting the right of the Lender to obtain control with respect to any Collateral, and (iii) all filings, registrations and recordings, which are
(A) required by the terms of this Agreement to have been given, made, obtained, done and accomplished, and (B) necessary to create, preserve, protect and perfect the security interest granted by the Borrower to the Lender hereby in respect
of the Collateral, have been given, made, obtained, done and accomplished. The Perfection Certificate 

 
delivered by the Borrower and all information set forth therein, is true and correct in all respects and Exhibit C sets forth a true and complete list of all of the Collateral as of the Closing
Date. 
 (j) Assigned Agreements. Each of the Assigned Agreements is in full force and effect and
constitutes the legal, valid and binding obligation of the Borrower, enforceable against the Borrower in accordance with its terms, except as may be limited by applicable bankruptcy, insolvency, reorganization, moratorium or similar law affecting
the enforcement of creditors’ rights generally and subject to general principles of equity (whether enforcement is sought by proceedings in equity or at law), and the Borrower has not assigned or pledged or otherwise encumbered the Assigned
Agreements to anyone other than the Lender. 
 (k) Intellectual Property. The Borrower is (i) the
true and lawful owner or licensee of the Trademarks listed on the Perfection Certificate and that said listed Trademarks constitute all the marks registered in the United States Patent and Trademark Office that the Borrower now owns or uses in
connection with the Picoplatin Technology, and (ii) the true and lawful owner or licensee of all rights in the Patents listed on the Perfection Certificate and that said Patents constitute all the United States patents and applications for
United States patents that the Borrower now owns or uses in connection with the Picoplatin Technology. 
 (l)
No Bankruptcy or Similar Event. (i) The Borrower has not made a general assignment for the benefit of creditors; (ii) no proceeding has been instituted by or against the Borrower seeking to adjudicate it a bankrupt or insolvent
person, or seeking liquidation, winding up, reorganization, arrangement, adjustment, protection, relief, or composition of it or its debt under any law relating to bankruptcy, insolvency or reorganization or relief of debtors, or seeking the entry
of an order for relief or the appointment of a receiver, trustee, or other similar official for it or for any substantial part of its property; seeking a warrant of attachment, execution or similar process against any substantial part of its
property, or any of the actions sought in such proceeding (including, without limitation, the entry of an order for relief against, or the appointment of a receiver, trustee, custodian or other similar official for, or for any substantial part of,
its property) shall occur; and (iii) the Borrower has not taken any corporate action to authorize any of the actions set forth above. 
 4. Creation of Security Interests. 
 (a) Grant of
Security Interest in Collateral. The Borrower hereby pledges, sells, assigns, and transfers to the Lender and grants to the Lender, to secure the payment and performance in full of the Note and the performance of each of Borrower’s
obligations and duties under this Agreement and the other Transaction Documents (the “Obligations”), a continuing security interest in all of the right, title and interest of the Borrower in, to and under all the property
described in Exhibit E hereto (the “Collateral”). The Borrower warrants and represents that the security interest granted herein shall be a first priority exclusive security interest in the Collateral. The security
interest hereunder is granted as security only and shall not subject the Lender to, or in any way alter or modify, any obligation or liability of the Borrower with respect to or arising out of any of the Collateral. 

(b) Grant of Security Interest in Agreements. As collateral security for the performance and payment in full of all
the Obligations, the Borrower hereby collaterally assigns and 

 
transfers to and grants a security interest to the Lender in, all right, title and interest of the Borrower in, to and under: (a) the Baxter Supply Agreement, the Heraeus Commercial
Manufacturing Agreement, the Heraeus Manufacturing Agreement and the AnorMed License Agreement and the Contract Rights (collectively, the “Assigned Agreements”), in each case including but not limited to, any and all rights
of enforcement with respect to representations and warranties, rights of indemnification, reservations of rights, assignments of warranties, whenever arising or coming into existence; (b) all payments, income and monies now or hereafter due,
paid or payable from the Borrower and its assigns under the Assigned Agreements (collectively “Payments”); and (c) all Proceeds of the foregoing. The Collateral shall include the Assigned Agreements and Payments for all
purposes. 
 (i) Notwithstanding the foregoing, the security interest hereunder is granted as security only and
the Borrower expressly agrees that it shall remain liable under each of the Assigned Agreements to perform all of the conditions and obligations provided therein to be observed and performed by it, and neither this Agreement nor any action taken
hereunder, shall cause the Lender to be under any obligation or liability in any respect to any party to any Assigned Agreement for the performance or observance of any of the representations, warranties, conditions, covenants, agreements or terms
thereof. 
 (ii) Upon the occurrence and during the continuance of an Event of Default, the Lender may enforce,
either in its own name or in the name of the Borrower, all rights of the Borrower under each and any of the Assigned Agreements in accordance with the terms thereof, and may: (A) compromise or settle any disputed claims as to rights of the
Borrower thereunder; (B) give releases or acquittances of rights of the Borrower thereunder; or (C) do any and all things necessary, convenient or proper to fully and completely effectuate the collateral assignment of the rights of the
Borrower thereunder pursuant hereto. 
 (c) Power of Attorney. The Borrower hereby irrevocably appoints
the Lender and its successors and assigns, the true and lawful attorney-in-fact of the Borrower, with full power (in the name of the Borrower or otherwise) and without any further act of the Borrower, to take any or all action and to execute and
deliver in the name and on behalf of the Borrower any and all financing statements, assignments, and other documents necessary to perfect, protect, preserve the security interests created hereunder and exercise the Lender’s rights under this
Agreement. After the occurrence and during the continuation of an Event of Default (as defined in the Note) and in addition to the Lender’s rights set forth in Section 4 below and the Note, the Lender shall be entitled: in accordance with
applicable law, to convert the Collateral into cash at the sole cost and expense of the Borrower, but solely for the benefit of Lender; to compromise, settle or execute releases with any of the Borrower’s account debtors, and to prosecute,
defend, compromise or release any action relating to the Collateral; to endorse the name of the Borrower in favor of the Lender upon any and all checks, drafts, money orders, notes, acceptances or other instruments pertaining to Collateral; to
receive any of the Collateral, or documents of title relating to the Collateral; to sign the name of the Borrower on any notice to the account debtors or on verification of the Collateral; to sell, assign, transfer, make any agreement in respect of,
or otherwise deal with or exercise rights in aspect of, any Collateral or the goods or services which have given rise thereto; and to execute and deliver all assignments, conveyances, statements, financing statements, renewal financing statements,
security agreements, affidavits, notices and other agreements, instruments and documents that the Lender 

 
may determine necessary in order to perfect and maintain the security interests and liens granted in this Agreement and in order to fully consummate all of the transactions contemplated therein.
Notwithstanding anything to the contrary in this Section 4, the Lender shall not have any obligation or liability by reason of or arising out of this Agreement to make any inquiry as to the nature or sufficiency of, to present or file any claim
with respect to, or to take any action to collect or enforce the payment of, any amounts to which it may be entitled at any time or times by virtue of this Agreement. This power of attorney is a power coupled with an interest and shall be
irrevocable. This power of attorney shall automatically terminate upon satisfaction of the Obligations (other than inchoate indemnity obligations and any other obligations which, by their terms, are to survive the termination of this Agreement).

 (d) Financing Statements; Further Assurances. The Borrower irrevocably authorizes the Lender at any
time and from time to time to file in any jurisdiction any initial financing statements and all amendments thereto that contain any information required pursuant to the UCC for the sufficiency or filing office acceptance of any financing statement
or amendment. The Borrower agrees to execute and deliver to the Lender from time to time, upon Lender’s request, all such documents and instruments, including without limitation, financing statements, supplements to this Agreement, notices of
assignments under statutes and regulations, and to take all such action, as the Lender may reasonably deem necessary or proper to perfect or otherwise preserve and protect the security interests and liens created hereby. 

(e) Collateral Release. Upon satisfaction of the Obligations in full, any and all security interest in the
Collateral and other collateral rights granted under this Agreement or otherwise in connection with the Obligations will automatically terminate. The Lender shall promptly upon the Borrower’s request make any filings necessary to terminate,
release or cancel any filings or recordings evidencing such security interests. 
 5. Lender’s Rights and
Remedies. 
 (a) While an Event of Default occurs and continues, Lender may, without notice or demand, do
any or all of the following: 
 (i) declare all Obligations immediately due and payable, without presentment,
demand, protest or other notice of any kind, all of which are hereby waived by the Borrower; 
 (ii) take
possession of the Collateral and make any payments and do any acts it considers necessary or reasonable to protect the Collateral and/or its security interest in the Collateral; and 

(iii) exercise all rights and remedies available to Lenders under the Transaction Documents or at law or equity, including
all remedies provided under the UCC. 
 (b) For the purpose of enabling the Lender to exercise rights and
remedies under this Agreement at such time as the Lender shall be lawfully entitled to exercise such rights and remedies and for no other purpose, the Borrower hereby grants to the Lender an irrevocable,
non-

 
exclusive license (exercisable without payment of royalty or other compensation to the Borrower) to use, assign or sublicense any of the Intellectual Property, including in such license
reasonable access to all media in which any of the licensed items may be recorded or stored and to all computer programs used for the compilation or printout thereof. 

(c) While an Event of Default occurs and continues, subject to any required consents referenced in Section 6(a)
below, the Lender may, by written notice to the Borrower, take any or all of the following actions: (i) declare the entire right, title and interest of the Borrower in and to each of the Patents and Trademarks, together with all trademark
rights and rights of protection to the same, vested, in which event such rights, title and interest shall immediately vest in the Lender, in which case the Borrower agrees to execute an assignment in form and substance reasonably satisfactory to the
Lender of all its rights, title and interest in and to the Patents and Trademarks to the Lender; (ii) take and practice or sell the Patents and take and use or sell the Trademarks and the good will of the Borrower’s business symbolized by
the Trademarks and the right to carry on the business and use the assets of the Borrower in connection with which the Trademarks have been used; and (iii) direct the Borrower to refrain, in which event the Borrower shall refrain, from using the
Patents and Trademarks in any manner whatsoever, directly or indirectly, and, if requested by the Lender, change the Borrower’s corporate name to eliminate therefrom any use of any mark and execute such other and further documents that the
Lender may request in connection with the Borrower’s obligations under this Agreement and to transfer ownership of the Patents and Trademarks, and registrations and any pending trademark application, to the Lender. 

6. Obligations of Borrower Upon Event of Default. While an Event of Default (as defined in the Note) occurs and continues,
upon request by the Lender, the Borrower agrees to: 
 (a) seek any consent required to transfer or assign all or
part of the Collateral to the Lender or the Lender’s designee or grant an exclusive license or sublicense to all or part of the Collateral to the Lender or its designees; and 

(b) assign to Lender any investigational new drug application (IND) or other regulatory approval pertaining to the
Collateral and in the name of the Lender, to the extent assignable. 
 7. Conditions to Closing of the Lender. The
Lender’s obligations hereunder at the Closing are subject to the fulfillment, on or prior to the Closing Date, of all of the following conditions, any of which may be waived in whole or in part by the Lender: 

(a) Representations and Warranties. The representations and warranties made by the Borrower in
Section 3 hereof shall have been true and correct when made, and shall be true and correct on the Closing Date. 
 (b) No Event of Default. No Event of Default or event or condition which upon notice, lapse of time or both would become an Event of Default shall have occurred and be continuing. 

 (c) Transaction Documents. The Borrower shall have duly executed and
delivered to the Lender the following documents: 
 (i) this Agreement; 

(ii) the Note; 
 (iii) the other Transaction Documents; and 
 (iv) all UCC-1
financing statements and other documents and instruments that the Lender may reasonably request to perfect its security interest in the Collateral. 
 (d) Fees and Expenses. The Lender shall have received all fees required to be paid, and all expenses. 
 (e) Lien Searches. The Lender shall have received the results of a recent lien search in each of the jurisdictions where the Collateral is located, and such search shall reveal no liens on any of
the Collateral, except for liens discharged on or prior to the Closing Date pursuant to documentation satisfactory to the Lender. 
 (f) Merger Closing. The Merger (as defined in the Merger Agreement) shall have been consummated and become effective. 

(g) Other Documents. The Lender shall have received such other documents as the Lender or its counsel may have
reasonably requested 
 8. Borrower Covenants. For so long as there are any outstanding Obligations, the Borrower
agrees: 
 (a) No Liens. The Borrower shall not, without first obtaining the prior written approval of
lender create, incur, or allow any mortgage, lien, deed of trust, charge, pledge, security interest or other encumbrance on any Collateral or permit any Collateral not to be subject to the first priority security interest granted herein. In
addition, the Borrower shall not sell, transfer, assign, mortgage, pledge, lease, license, grant a security interest in, or encumber, or enter into any agreement, document, instrument or other arrangement (except with or in favor of the Lender)
which directly or indirectly prohibits or has the effect of prohibiting the Borrower from selling, transferring, assigning, mortgaging, pledging, leasing, licensing, granting a security interest in or upon, or encumbering any of the Intellectual
Property included in the Collateral. 
 (b) No Bankruptcy Filing. The Borrower shall not, without first
obtaining the prior written approval of the Lender, file a petition for bankruptcy or permit or suffer any receiver, trustee or assignee for the benefit of creditors, or any other custodian to be appointed to take possession of all or any of the
assets of the Borrower. 
 (c) Place of Business. The Borrower shall not (a) change its state of
organization, (b) change the location of its chief executive office/chief place of business or remove its books and records from the location specified in this Agreement, or (c) change its name, identity or structure to

 
such an extent that any financing statement filed in connection with this Agreement would become ineffective or seriously misleading, unless it shall have given Lender at least 30 days’
prior written notice thereof, provided that the Borrower shall be permitted to change its name to “Allozyne, Inc.” upon consummation of the Merger (as defined in the Merger Agreement). 

(d) Notices. The Borrower shall promptly furnish the Lender written notice of (i) the occurrence of an Event
of Default or event or condition which upon notice, lapse of time or both would become an Event of Default, (ii) any lien or claim asserted against any of the Collateral, and (iii) any breach or default, or notice thereof received from a
counterparty, under any of the Assigned Agreements. 
 (e) Use of Proceeds. The proceeds of the Note will
be used by the Borrower to fund in whole or in part the [Acquiror Severance Obligation and the Acquiror Gross-Up Obligation (as such terms are defined in the Merger Agreement). 

(f) Assigned Agreements. The Borrower will (i) not assign, pledge or otherwise encumber any of its right,
title or interest under, in or to any of the Assigned Agreements or Payments, to anyone other than the Lender or its successors or assigns; (ii) not, without the prior written consent of the Lender, take any action, the taking of which could
reasonably be expected to result in a material alteration or impairment of any of the Assigned Agreements or of any of the Transaction Documents which is materially adverse to the interests of the Lender; (iii) not, without the prior written
consent of the Lender (such consent not to be unreasonably withheld or delayed), deliver any notice of termination or terminate any of the Assigned Agreements; (iv) exercise promptly and diligently each and every material right which it may
have under each of the Assigned Agreements as and to the extent requested by the Lender (except the right to terminate subject to the provision set forth above); and (v) deliver to the Lender a copy of each demand, notice, communication or
document (except those received in the ordinary course of business and not relating to the amendment or termination thereof, or any breach thereunder by any party) delivered to it in any way relating to any of the Assigned Agreements, the subject
matter of which could reasonably be expected to be materially adverse to the interests of the Lender. 
 (g)
Infringements. The Borrower shall: (i) diligently prosecute, protect, defend and maintain the validity and enforceability of and all rights under the Intellectual Property material to the Borrower’s business and to the extent
commercially reasonable; (ii) promptly advise the Lender in writing of material infringements of the Intellectual Property that become known to the Board of Directors of the Borrower; and (iii) not allow any Intellectual Property material
to the Borrower’s business to be abandoned, forfeited or dedicated to the public without the Lender’s written consent, which consent shall not be unreasonably withheld or delayed. 

(h) Collateral Assignments; Further Assurances. Upon request of the Lender whenever made, the Borrower shall
promptly execute and deliver to the Lender such Collateral Assignment Agreements as the Lender shall request in connection with the Intellectual Property. The Borrower agrees that it will take such action, and deliver such documents or instruments,
as the Lender shall request in connection with the preparation, filing or registration and enforcement of any Collateral Assignment Agreement. 

 9. Lender Covenants. Notwithstanding anything to the contrary in this
Agreement, the Lender shall not enter into, and shall require that any transferees or licensees of any interest in the Collateral shall not enter into, any agreement or arrangement with W.C. Heraeus GmbH or its affiliates (collectively
“Heraeus”) for the supply of Picoplatin API without assuming the obligation of the Borrower to repay the cost of the dedicated equipment in the amount of €958,000 pursuant to Section 5.3 of the Heraeus Commercial Manufacturing
Agreement (the “Heraeus Obligation”) and, in the event that any portion of the Heraeus Obligation is paid by the Borrower, reimbursing the Borrower for payment of such portion of the Heraeus Obligation, provided that such
obligations may be renegotiated by the Lender with the consent of the Borrower, which consent shall not be unreasonably withheld or delayed. 
 10. Miscellaneous. 
 (a) No Transfers of Notes;
Successors and Assigns. This Agreement binds and is for the benefit of the successors and permitted assigns of each party. Borrower may not assign this Agreement or any rights or Obligations under it without the Lenders’ prior written
consent which may be granted or withheld in the Lenders’ discretion. 
 (b) Waivers and Amendments.
Any provision of this Agreement may be amended, waived or modified only upon the written consent of the Borrower and the Lender. No purported amendment or modification of any Transaction Document, or waiver, discharge or termination of any
obligation under any Transaction Document, shall be enforceable or admissible unless, and only to the extent, expressly set forth in a writing signed by the party against which enforcement or admission is sought. Without limiting the generality of
the foregoing, no oral promise or statement, nor any action, inaction, delay, failure to require performance or course of conduct shall operate as, or evidence, an amendment, supplement or waiver or have any other effect on any Transaction Document.
Any waiver granted shall be limited to the specific circumstance expressly described in it, and shall not apply to any subsequent or other circumstance, whether similar or dissimilar, or give rise to, or evidence, any obligation or commitment to
grant any further waiver 
 (c) Nature of Relationship. Lender and Borrower intend that the relationship
between them shall be solely that of creditor and debtor. Nothing in this Agreement shall be construed to create a partnership or any other relationship which would make Lender in any way responsible or liable for the debts, losses, obligations or
duties of Borrower 
 (d) Governing Law. This Agreement and all actions arising out of or in connection
with this Agreement shall be governed by and construed in accordance with the laws of the State of Washington, without regard to the conflicts of law provisions of the State of Washington or of any other state. 

(e) Survival. The representations, warranties, covenants and agreements made herein shall survive the execution and
delivery of this Agreement and the closing of the transactions contemplated herein. 
 (f) Entire
Agreement. This Agreement together with the Note constitute and contain the entire agreement among the Borrower and the Lender and supersede any and all prior 

 
agreements, negotiations, correspondence, understandings and communications among the parties, whether written or oral, respecting the subject matter hereof. 

(g) Notices. All notices, requests, demands, consents, instructions or other communications required or permitted
hereunder shall be in writing and faxed, mailed or delivered to each party as follows: (i) if to the Lender, at 750 Battery Street, Suite 400, San Francisco, California 94111, Attention: Managing Director, or at such other address as Lender
shall furnish the Borrower in writing, and (ii) if to the Borrower, at Poniard Pharmaceuticals, Inc., [
                                         
                                         
   ] Attention: Chief Executive Officer facsimile: [(              )              -
            ], or at such other address or facsimile number as the Borrower shall have furnished to the Lender in writing, with a copy to Perkins Coie LLP, 1201 Third Avenue, Suite
4800, Seattle, Washington 98101, Attention James R. Lisbakken, Esq. All such notices and communications will be deemed effectively given the earlier of (i) when received, (ii) when delivered personally, (iii) one business day after
being delivered by facsimile (with receipt of appropriate confirmation), (iv) one business day after being deposited with an overnight courier service of recognized standing or (v) four days after being deposited in the U.S. mail, first
class with postage prepaid. 
 (h) Expenses. The Borrower and the Lender shall each bear their own costs
incurred in connection with the preparation, execution and delivery of this Agreement and the Note. 
 (i)
Severability of this Agreement. If any provision of this Agreement shall be judicially determined to be invalid, illegal or unenforceable, the validity, legality and enforceability of the remaining provisions shall not in any way be affected
or impaired thereby. 
 (j) Counterparts. This Agreement may be executed in one or more counterparts, each
of which will be deemed an original, but all of which together will constitute one and the same agreement. Facsimile copies of signed signature pages will be deemed binding originals. 

[Remainder of page intentionally left blank.] 

 The parties have caused this Agreement to be duly executed and delivered by their proper and
duly authorized officers as of the date and year first written above. 
  

			
	BORROWER:
	
	PONIARD PHARMACEUTICALS, INC.
		
	By:	 	 
	Print Name:	 	 
	Title:	 	 

  

			
	LENDER:
	
	BAY CITY CAPITAL FUND IV, L.P.
	
	By: Bay City Capital Management IV LLC,
its general partner
	
	By: Bay City Capital LLC, its manager
		
	By:	 	 
	Name:	 	 
	Title:	 	Managing Director

 Poniard Pharmaceuticals, Inc. 

[Signature Page to Loan and Security Agreement] 

 EXHIBIT A 
 COLLATERAL ASSIGNMENT OF PATENTS 
 COLLATERAL ASSIGNMENT OF PATENTS dated as of
            , 2011 (this “Agreement”), between PONIARD PHARMACEUTICALS, INC., a Washington corporation (together with its successors and assigns, the
“Borrower”), and BAY CITY CAPITAL FUND IV, L.P., a Delaware limited partnership, as lender (together with its successors and assigns in such capacity, the “Lender): 

RECITALS: 
 (1) This Agreement
is made pursuant to the Loan and Security Agreement, dated as of             , 2011 (as amended, restated or otherwise modified from time to time, the “Loan
Agreement”), between the Borrower and the Lender. 
 (2) The Borrower has granted to the Lender under the Loan Agreement a continuing
security interest in, assignment of and lien on certain of its assets related to the Picoplatin Technology, whether now owned or existing or hereafter acquired or arising. 
 NOW, THEREFORE, in consideration of the foregoing, the mutual covenants contained herein and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the
Borrower hereby covenants and agrees with the Lender as follows: 
 Section 1. Defined Terms. Terns used herein without definition
shall have the respective meanings ascribed thereto in the Loan Agreement. 
 Section 2. Assignment and Grant of Security Interest.
As security for the prompt payment and performance of the Obligations, the Borrower hereby assigns, transfers, conveys and grants to the Lender a security interest in, a general lien upon and/or a right of set-off against (whether now owned or
hereafter acquired by the Borrower and whether acquired in the United States or elsewhere in the world) all right, title and interest of the Borrower in and to the following, whether now existing or hereafter acquired: 

(i) all of the Patents issued by the United States Patent and Trademark Office listed on Schedule A to this Agreement;

 (ii) all applications for Patents to be issued by the United States Patent and Trademark Office listed on
Schedule A to this Agreement); 
 (iii) all Patents issued by any other country or any office, agency or other
governmental authority thereof and that are listed on Schedule A to this Agreement; 
 (iv) all applications for
Patents to be issued by any office, agency or other governmental authority referred to in clause (iii) above and that are listed on Schedule A to this Agreement; 

(v) all registrations and recordings with respect to any of the foregoing; 

(vi) all reissues, continuations, continuations-in-part, extensions and divisions of any of the foregoing; 

(vii) all licenses of any Patents, inventions, processes, production methods, proprietary information or know-how covered by any of the
foregoing, including all rights to payments in respect thereof; 
 (viii) all rights to sue for past, present or future
infringements of any of the foregoing; 

  
 E-1

 (ix) to the extent not included above, all general intangibles (as such term is defined in
the UCC) of the Borrower representing the foregoing; and 
 (xi) all proceeds of any and all of the foregoing. 

Section 3. Reference to Separate Loan Agreement. This Agreement has been entered into by the Borrower and the Lender primarily for recording
purposes as contemplated by the Loan Agreement, dated as of the date hereof, between the Borrower, as debtor, and the Lender, as secured party. In the event of any inconsistency between any of the terms or provisions hereof and the terms and
provisions of such Loan Agreement, the terms and provisions of such Loan Agreement shall govern. 
 IN WITNESS WHEREOF, the parties hereto have
caused this Agreement to be executed and delivered by their duly authorized officers as of the date first set forth above. 
  

			
	PONIARD PHARMACEUTICALS, INC.
		
	By:	 	 
		 	Name:
		 	Title:

 Accepted and acknowledged by: 
  

			
	BAY CITY CAPITAL FUND IV, L.P.
	
	 By: Bay City Capital Management IV LLC,
 its general partner

	
	By: Bay City Capital LLC, its manager
		
	By:	 	 
	Name:	 	
	Title:	 	Managing Director

  
 E-2

 Schedule A 
 to Collateral Assignment of Patents 
  

									
	 Serial #
	  	Filing Date	  	Country	  	 Title
	  	Status
	60/857,067	  	11/6/2006	  	US	  	USE OF PICOPLATIN TO TREAT SMALL CELL LUNG CANCER	  	CONVERTED
					
	60/877,515	  	12/28/2006	  	US	  	USE OF PICOPLATIN TO TREAT SMALL CELL LUNG CANCER	  	CONVERTED
					
	60/927,347	  	5/3/2007	  	US	  	USE OF PICOPLATIN TO TREAT SMALL CELL LUNG CANCER	  	CONVERTED
					
	60/931,309	  	5/22/2007	  	US	  	USE OF PICOPLATIN TO TREAT SMALL CELL LUNG CANCER	  	CONVERTED
					
	60/969,441	  	8/31/2007	  	US	  	USE OF PICOPLATIN TO TREAT SMALL CELL LUNG CANCER	  	CONVERTED
					
	12/508,392	  	7/23/2009	  	US	  	USE OF PICOPLATIN TO TREAT SMALL CELL LUNG CANCER	  	PENDING
					
	60/857,017	  	11/6/2006	  	US	  	A METHOD OF TREATMENT OF HORMONE-RESISTANT PROSTATE CANCER	  	CONVERTED
					
	60/857,564	  	11/8/2006	  	US	  	A METHOD OF TREATMENT OF HORMONE-RESISTANT PROSTATE CANCER	  	CONVERTED
					
	60/877,570	  	12/28/2006	  	US	  	A METHOD OF TREATMENT OF HORMONE-RESISTANT PROSTATE CANCER	  	CONVERTED
					
	60/889,179	  	2/9/2007	  	US	  	USE OF PICOPLATIN TO TREAT PROSTATE CANCER	  	CONVERTED
					
	60/890,950	  	2/21/2007	  	US	  	USE OF PICOPLATIN TO TREAT PROSTATE CANCER	  	CONVERTED
					
	60/931,609	  	5/24/2007	  	US	  	USE OF PICOPLATIN TO TREAT PROSTATE CANCER	  	CONVERTED
					
	60/952,440	  	7/27/2007	  	US	  	USE OF PICOPLATIN TO TREAT PROSTATE CANCER	  	CONVERTED
					
	11/935,979	  	11/6/2007	  	US	  	USE OF PICOPLATIN TO TREAT PROSTATE CANCER	  	PENDING
					
	60/857,066	  	11/6/2006	  	US	  	A METHOD OF TREATMENT OF COLORECTAL CANCER	  	CONVERTED
					
	60/857/725	  	11/8/2006	  	US	  	A METHOD OF TREATMENT OF COLORECTAL CANCER	  	CONVERTED
					
	60/889,191	  	2/9/2007	  	US	  	USE OF PICOPLATIN TO TREAT COLORECTAL CANCER	  	CONVERTED
					
	60/931,589	  	5/24/2007	  	US	  	USE OF PICOPLATIN TO TREAT COLORECTAL CANCER	  	CONVERTED
					
	60/683,852	  	10/30/2007	  	US	  	USE OF PICOPLATIN TO TREAT COLORECTAL CANCER	  	CONVERTED
					
	12/367,394	  	2/6/2009	  	US	  	USE OF PICOPLATIN TO TREAT COLORECTAL CANCER	  	PENDING
					
	12/465,563	  	5/13/2009	  	US	  	USE OF PICOPLATIN TO TREAT COLORECTAL CANCER	  	PENDING
					
	12/508,372	  	7/23/2009	  	US	  	USE OF PICOPLATIN TO TREAT COLORECTAL CANCER	  	PENDING
					
	PCT/US2010/34593	  	5/12/2010	  	PCT	  	USE OF PICOPLATIN TO TREAT COLORECTAL CANCER	  	PENDING
					
	60/889,201	  	2/9/2007	  	US	  	ENCAPSULATED PICOPLATIN	  	CONVERTED

  
 E-3

									
					
	60/889,675	  	2/13/2007	  	US	  	ENCAPSULATED PICOPLATIN	  	CONVERTED
					
	60/984,156	  	10/31/2007	  	US	  	ENCAPSULATED PICOPLATIN	  	CONVERTED
					
	60/989,020	  	11/19/2007	  	US	  	ENCAPSULATED PICOPLATIN	  	CONVERTED
					
	PCT/US2008/001746	  	2/8/2009	  	PCT	  	ENCAPSULATED PICOPLATIN	  	NATIONAL PHASE
					
	12/536,311	  	8/5/2009	  	US	  	ENCAPSULATED PICOPLATIN	  	PENDING
					
	2008214199	  	2/8/2008	  	AU	  	ENCAPSULATED PICOPLATIN	  	PENDING
					
	PI 0806362-1	  	2/8/2008	  	BR	  	ENCAPSULATED PICOPLATIN	  	PENDING
					
	2,677,639	  	2/8/2008	  	CA	  	ENCAPSULATED PICOPLATIN	  	PENDING
					
	200880011347.9	  	2/8/2008	  	CN	  	ENCAPSULATED PICOPLATIN	  	PENDING
					
	1200/2009	  	2/8/2008	  	EG	  	ENCAPSULATED PICOPLATIN	  	PENDING
					
	08725387.8	  	2/8/2008	  	EP	  	ENCAPSULATED PICOPLATIN	  	PENDING
					
	10102719.4	  	2/8/2008	  	HK	  	ENCAPSULATED PICOPLATIN	  	PENDING
					
	W-00200902208	  	2/8/2008	  	ID	  	ENCAPSULATED PICOPLATIN	  	PENDING
					
	200261	  	2/8/2008	  	IL	  	ENCAPSULATED PICOPLATIN	  	PENDING
					
	5257/CHENP/2009	  	2/8/2008	  	IN	  	ENCAPSULATED PICOPLATIN	  	PENDING
					
	2009-549126	  	2/8/2008	  	JP	  	ENCAPSULATED PICOPLATIN	  	PENDING
					
	10-2009-7018781	  	2/8/2008	  	KR	  	ENCAPSULATED PICOPLATIN	  	PENDING
					
	MX/s/2009/008487	  	2/8/2008	  	MX	  	ENCAPSULATED PICOPLATIN	  	PENDING
					
	1-2009-501520	  	2/8/2008	  	PH	  	ENCAPSULATED PICOPLATIN	  	PENDING
					
	2009133447	  	2/8/2008	  	RU	  	ENCAPSULATED PICOPLATIN	  	PENDING
					
	200909261	  	2/8/2008	  	UA	  	ENCAPSULATED PICOPLATIN	  	PENDING
					
	1-2009-01904	  	2/8/2008	  	VN	  	ENCAPSULATED PICOPLATIN	  	PENDING
					
	60/889,171*	  	2/9/2007	  	US	  	STABILIZED PICOPLATIN ORAL DOSAGE FORM	  	CONVERTED
					
	60/889,681*	  	2/13/2007	  	US	  	STABILIZED PICOPLATIN ORAL DOSAGE FORM	  	CONVERTED
					
	PCT/US2008/001752*	  	2/8/2008	  	PCT	  	STABILIZED PICOPLATIN ORAL DOSAGE FORM	  	NATIONAL PHASE
					
	12/536,335*	  	8/5/2009	  	US	  	STABILIZED PICOPLATIN ORAL DOSAGE FORM	  	PENDING
					
	2008214202*	  	2/8/2008	  	AU	  	STABILIZED PICOPLATIN ORAL DOSAGE FORM	  	PENDING
					
	0806418-0*	  	2/8/2008	  	BR	  	STABILIZED PICOPLATIN ORAL DOSAGE FORM	  	PENDING
					
	2,677,640*	  	2/8/2008	  	CA	  	STABILIZED PICOPLATIN ORAL DOSAGE FORM	  	PENDING
					
	200880011357.2*	  	2/8/2008	  	CN	  	STABILIZED PICOPLATIN ORAL DOSAGE FORM	  	PENDING
					
	1201/2009*	  	2/8/2008	  	EG	  	STABILIZED PICOPLATIN ORAL DOSAGE FORM	  	PENDING
					
	08725393.6*	  	2/8/2008	  	EP	  	STABILIZED PICOPLATIN ORAL DOSAGE FORM	  	PENDING
					
	10106157.4*	  	2/8/2008	  	HK	  	STABILIZED PICOPLATIN ORAL DOSAGE FORM	  	PENDING
					
	W-00200902207*	  	2/8/2008	  	ID	  	STABILIZED PICOPLATIN ORAL DOSAGE FORM	  	PENDING
					
	200262*	  	2/8/2008	  	IL	  	STABILIZED PICOPLATIN ORAL DOSAGE FORM	  	PENDING
					
	5256/CHENP/2009*	  	2/8/2008	  	IN	  	STABILIZED PICOPLATIN ORAL DOSAGE FORM	  	PENDING

  

	*	Co-owned with Genzyme Corporation 

  
 E-4

									
					
	2009-549128*	  	2/8/2008	  	JP	  	STABILIZED PICOPLATIN ORAL DOSAGE FORM	  	PENDING
					
	10-2009-7018780*	  	2/8/208	  	KR	  	STABILIZED PICOPLATIN ORAL DOSAGE FORM	  	PENDING
					
	MX/a/2009/008488*	  	2/8/2008	  	MX	  	STABILIZED PICOPLATIN ORAL DOSAGE FORM	  	PENDING
					
	1-2009-501521*	  	2/8/2008	  	PH	  	STABILIZED PICOPLATIN ORAL DOSAGE FORM	  	PENDING
					
	2009133446*	  	2/8/2008	  	RU	  	STABILIZED PICOPLATIN ORAL DOSAGE FORM	  	PENDING
					
	200909262*	  	2/8/2008	  	UA	  	STABILIZED PICOPLATIN ORAL DOSAGE FORM	  	PENDING
					
	1-2009-01903*	  	2/8/2008	  	VN	  	STABILIZED PICOPLATIN ORAL DOSAGE FORM AND PROCESS FOR PREPARING THE SAME	  	PENDING
					
	60/949,639	  	6/27/2007	  	US	  	STABILIZED INTRAVENOUS DOSAGE FORM	  	CONVERTED
					
	60/950,033	  	7/16/2007	  	US	  	ORAL FORMULATION FOR PICOPLATIN	  	CONVERTED
					
	61/043,962	  	4/10/2008	  	US	  	ORAL FORMULATION FOR PICOPLATIN	  	CONVERTED
					
	PCT/US2008/008669	  	7/16/2008	  	PCT	  	ORAL FORMULATION FOR PICOPLATIN	  	NATIONAL PHASE
					
	12/669,274	  	1/15/2010	  	US	  	ORAL FORMULATION FOR PICOPLATIN	  	PENDING
					
	2,693,057	  	7/16/2008	  	CA	  	ORAL FORMULATION FOR PICOPLATIN	  	PENDING
					
	200880103323.6	  	7/16/2008	  	CN	  	ORAL FORMULATION FOR PICOPLATIN	  	PENDING
					
	08780206.2	  	7/16/2008	  	EP	  	ORAL FORMULATION FOR PICOPLATIN	  	PENDING
					
	11101572.1	  	7/16/2008	  	HK	  	ORAL FORMULATION FOR PICOPLATIN	  	PENDING
					
	2010-517010	  	7/16/2008	  	JP	  	ORAL FORMULATION FOR PICOPLATIN	  	PENDING
					
	097127053	  	7/16/2008	  	TW	  	ORAL FORMULATION FOR PICOPLATIN	  	PENDING
					
	61/027,387	  	2/8/2008	  	US	  	USE OF PICOPLATIN AND BEVACIZUMAB TO TREAT COLORECTAL CANCER	  	CONVERTED
					
	PCT/US2009/000770	  	2/6/2009	  	PCT	  	USE OF PICOPLATIN AND BEVACIZUMAB TO TREAT COLORECTAL CANCER	  	NATIONAL PHASE
					
	12/866,702	  	11/11/2010	  	US	  	USE OF PICOPLATIN AND BEVACIZUMAB TO TREAT COLORECTAL CANCER	  	PENDING
					
	2009210654	  	2/6/2009	  	AU	  	USE OF PICOPLATIN AND BEVACIZUMAB TO TREAT COLORECTAL CANCER	  	PENDING
					
	2,715,348	  	2/6/2009	  	CA	  	USE OF PICOPLATIN AND BEVACIZUMAB TO TREAT COLORECTAL CANCER	  	PENDING
					
	200980109758.6	  	2/6/2009	  	CN	  	USE OF PICOPLATIN AND BEVACIZUMAB TO TREAT COLORECTAL CANCER	  	PENDING
					
	09708527.8	  	2/6/2009	  	EP	  	USE OF PICOPLATIN AND BEVACIZUMAB TO TREAT COLORECTAL CANCER	  	PENDING
					
	2010-545883	  	2/6/2009	  	JP	  	USE OF PICOPLATIN AND BEVACIZUMAB TO TREAT COLORECTAL CANCER	  	PENDING
					
	61/027,382	  	2/8/2008	  	US	  	USE OF PICOPLATIN AND BEVACIZUMAB TO TREAT COLORECTAL CANCER	  	CONVERTED
					
	PCT/US2009/000773	  	2/6/2009	  	PCT	  	USE OF PICOPLATIN AND BEVACIZUMAB TO TREAT COLORECTAL CANCER	  	NATIONAL PHASE
					
	12/866,706	  	11/15/2010	  	US	  	USE OF PICOPLATIN AND BEVACIZUMAB TO TREAT COLORECTAL CANCER	  	PENDING
					
	2009210656	  	2/6/2009	  	AU	  	USE OF PICOPLATIN AND BEVACIZUMAB TO TREAT COLORECTAL CANCER	  	PENDING
					
	2,715,353	  	2/6/2009	  	CA	  	USE OF PICOPLATIN AND BEVACIZUMAB TO TREAT COLORECTAL CANCER	  	PENDING
					
	200980111015.2	  	2/6/2009	  	CN	  	USE OF PICOPLATIN AND BEVACIZUMAB TO TREAT COLORECTAL CANCER	  	PENDING

  

	*	Co-owned with Genzyme Corporation 

  
 E-5

									
					
	09708387.7	  	2/6/2009	  	EP	  	USE OF PICOPLATIN AND BEVACIZUMAB TO TREAT COLORECTAL CANCER	  	PENDING
					
	2010-545885	  	2/6/2009	  	JP	  	USE OF PICOPLATIN AND BEVACIZUMAB TO TREAT COLORECTAL CANCER	  	PENDING
					
	61/027,360	  	2/8/2008	  	US	  	USE OF PICOPLATIN AND BEVACIZUMAB TO TREAT COLORECTAL CANCER	  	CONVERTED
					
	PCT/US2009/000750	  	2/6/2009	  	PCT	  	PICOPLATIN AND AMRUBICIN TO TREAT LUNG CANCER	  	NATIONAL PHASE
					
	12/866,710	  	11/10/2010	  	US	  	PICOPLATIN AND AMRUBICIN TO TREAT LUNG CANCER	  	PENDING
					
	2009210734	  	2/6/2009	  	AU	  	PICOPLATIN AND AMRUBICIN TO TREAT LUNG CANCER	  	PENDING
					
	2,715,329	  	2/6/2009	  	CA	  	PICOPLATIN AND AMRUBICIN TO TREAT LUNG CANCER	  	PENDING
					
	200980110139.9	  	2/6/2009	  	CN	  	PICOPLATIN AND AMRUBICIN TO TREAT LUNG CANCER	  	PENDING
					
	09708292.9	  	2/6/2009	  	EP	  	PICOPLATIN AND AMRUBICIN TO TREAT LUNG CANCER	  	PENDING
					
	2010-545878	  	2/6/2009	  	JP	  	PICOPLATIN AND AMRUBICIN TO TREAT LUNG CANCER	  	PENDING
					
	61/027,388	  	2/8/2008	  	US	  	COMBINATION CHEMOTHERAPY COMPRISING STABILIZED INTRAVENOUS PICOPLATIN DOSAGE FORM	  	CONVERTED
					
	61/055/071	  	5/21/2008	  	US	  	COMBINATION CHEMOTHERAPY COMPRISING STABILIZED INTRAVENOUS PICOPLATIN DOSAGE FORM	  	CONVERTED
					
	PCT/US2008/08076	  	6/27/2008	  	PCT	  	STABILIZED PICOPLATIN DOSAGE FORM	  	NATIONAL PHASE
					
	12/635,517	  	12/10/2009	  	US	  	STABILIZED PICOPLATIN DOSAGE FORM	  	PENDING
					
	12/635,534	  	12/10/2009	  	US	  	COMBINATION THERAPY FOR OVARIAN CANCER	  	PENDING
					
	12/781,599	  	5/17/2010	  	US	  	COMBINATION THERAPY FOR OVARIAN CANCER	  	PENDING
					
	PCT/US11/036855	  	5/17/2011	  	PCT	  	COMBINATION THERAPY FOR OVARIAN CANCER	  	PENDING
					
	2008295576	  	6/27/2008	  	AU	  	STABILIZED PICOPLATIN DOSAGE FORM	  	PENDING
					
	PI0811816-7	  	6/27/2008	  	BR	  	STABILIZED PICOPLATIN DOSAGE FORM	  	PENDING
					
	2,691,115	  	6/27/2008	  	CA	  	STABILIZED PICOPLATIN DOSAGE FORM	  	PENDING
					
	200880022248.0	  	6/27/2008	  	CN	  	STABILIZED PICOPLATIN DOSAGE FORM	  	PENDING
					
	08828991.3	  	6/27/2008	  	EP	  	STABILIZED PICOPLATIN DOSAGE FORM	  	PENDING
					
	10108170.3	  	6/27/2008	  	HK	  	STABILIZED PICOPLATIN DOSAGE FORM	  	PENDING
					
	W-00201000277	  	6/27/2008	  	ID	  	STABILIZED PICOPLATIN DOSAGE FORM	  	PENDING
					
		  	6/27/208	  	IL	  	STABILIZED PICOPLATIN DOSAGE FORM	  	PENDING
					
	7725/CHENP/2009	  	6/27/2008	  	IN	  	STABILIZED PICOPLATIN DOSAGE FORM	  	PENDING
					
	2010-514837	  	6/27/2008	  	JP	  	STABILIZED PICOPLATIN DOSAGE FORM	  	PENDING
					
	10-2010-7001745	  	6/27/2008	  	KR	  	STABILIZED PICOPLATIN DOSAGE FORM	  	PENDING
					
	MX/a/2009/013835	  	6/27/2008	  	MX	  	STABILIZED PICOPLATIN DOSAGE FORM	  	PENDING
					
	2010102096	  	6/27/2008	  	RU	  	STABILIZED PICOPLATIN DOSAGE FORM	  	PENDING
					
	097124033	  	6/28/2008	  	TW	  	STABILIZED PICOPLATIN DOSAGE FORM	  	PENDING
					
	201000817	  	6/28/2008	  	UA	  	STABILIZED PICOPLATIN DOSAGE FORM	  	PENDING
					
	61/169,679	  	4/15/2009	  	US	  	PICOPLATIN ORAL DOSAGE FORM HAVING HIGH BIOAVAILABILITY	  	CONVERTED
					
	61/170,487	  	4/17/2009	  	US	  	PICOPLATIN ORAL DOSAGE FORM HAVING HIGH BIOAVAILABILITY	  	CONVERTED

  
 E-6

									
					
	PCT/US2010/00735	  	3/11/2010	  	PCT	  	HIGH BIOVAILABILITY ORAL PICOPLATIN ANTI-CANCER THERAPY	  	PUBLISHED
					
	61/177,567	  	5/12/2009	  	US	  	USE OF PICOPLATIN TO TREAT PROSTATE CANCER	  	CONVERTED
					
	PCT/US2010/34591	  	5/12/2010	  	PCT	  	USE OF PICOPLATIN TO TREAT PROSTATE CANCER	  	PUBLISHED
					
	61/177,571	  	5/12/2009	  	US	  	USE OF PICOPLATING AND DOCETAXEL TO TREAT PROSTATE CANCER	  	CONVERTED
					
	61/186,526	  	6/12/2009	  	US	  	IMPROVED SYNTHESIS OF PICOPLATIN	  	CONVERTED
					
	PCT/US2010/38348	  	6/11/2010	  	PCT	  	IMPROVED SYNTHESIS OF PICOPLATIN	  	PUBLISHED
					
	099119171	  	6/11/2010	  	TW	  	IMPROVED SYNTHESIS OF PICOPLATIN	  	PENDING
					
	61/311,169	  	3/5/2010	  	US	  	METHOD TO TREAT SMALL CELL LUNG CANCER	  	CONVERTED
					
	61/345,442	  	5/17/2010	  	US	  	METHOD TO TREAT SMALL CELL LUNG CANCER	  	CONVERTED
					
	PCT/US2011/027264	  	3/4/2011	  	PCT	  	METHOD TO TREAT SMALL CELL LUNG CANCER	  	PENDING
					
	100107612	  	3/7/2011	  	TW	  	METHOD TO TREAT SMALL CELL LUNG CANCER	  	PENDING
					
	61/345,451	  	5/17/2010	  	US	  	COMBINATION THERAPY FOR SMALL CELL LUNG CANCER	  	CONVERTED
					
	61/346,777	  	5/20/2010	  	US	  	COMBINATION THERAPY FOR SMALL CELL LUNG CANCER	  	CONVERTED
					
	PCT/US2011/027268	  	3/4/2011	  	PCT	  	COMBINATION THERAPY FOR SMALL CELL LUNG CANCER	  	PENDING
					
	100107621	  	3/7/2011	  	TW	  	COMBINATION THERAPY FOR SMALL CELL LUNG CANCER	  	PENDING

  
 E-7

 EXHIBIT B 
 COLLATERAL ASSIGNMENT OF TRADEMARKS 
 COLLATERAL ASSIGNMENT OF TRADEMARKS dated as
of             , 2011 (“Agreement”), between PONIARD PHARMACEUTICALS, INC., a Washington corporation (together with its successors and assigns, the
“Borrower”), and BAY CITY CAPITAL FUND IV, L.P., a Delaware limited partnership, as Lender (together with its successors and assigns in such capacity, the “Lender”): 

RECITALS: 
 (1) This Agreement
is made pursuant to the Loan and Security Agreement, dated as of             , 2011 (as amended, restated or otherwise modified from time to time, the “Loan
Agreement”), between the Borrower and the Lender. 
 (2) The Borrower has granted to the Lender under the Loan Agreement a continuing
security interest in, assignment of and lien on certain of its assets related to the Picoplatin Technology, whether now owned or existing or hereafter acquired or arising. 
 NOW, THEREFORE, in consideration of the foregoing, the mutual covenants contained herein and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the
Borrower hereby covenants and agrees with the Lender as follows: 
 Section 1. Defined Terms. Terns used herein without definition
shall have the respective meanings ascribed thereto in the Loan Agreement. 
 Section 2. Assignment and Grant of Security Interest.
As security for the prompt payment and performance of the Obligations, the Borrower hereby assigns, transfers, conveys and grants to the Lender a security interest in, a general lien upon and/or a right of set-off against (whether now owned or
hereafter acquired by the Borrower and whether acquired in the United States or elsewhere in the world) all right, title and interest of the Borrower in and to the following, whether now existing or hereafter acquired: 

(i) all trademarks, trade names and service marks registered with the United States Patent and Trademark Office listed on
Schedule A to this Agreement; 
 (ii) all applications for the registration of trademarks, trade names and service
marks filed with the United States Patent and Trademark Office listed on Schedule A to this Agreement; 
 (iii) all
trademarks, trade names and service marks registered with any office, agency or other governmental authority of any State, the District of Columbia or any possession or territory of the United States and that are listed on Schedule A to
this Agreement; 
 (iv) all trademarks, trade names and service marks registered with any office, agency or other governmental
authority of any other country or any province, department or other governmental subdivision thereof and that are listed on Schedule A to this Agreement; 
 (v) all registrations and recordings with respect to any of the foregoing; 
 (vi)
all reissues, extensions and renewals of any of the foregoing; 
 (vii) all corporate names, business names, trade styles, logos,
other source or business identifiers; all information, customer lists, identification of supplier, data, plans, blueprints, specifications, designs, drawings, recorded knowledge, surveys, engineering reports, test reports, manuals, materials
standards, processing standards, performance standards, catalogs, computer and automatic machinery software and programs, and the like pertaining to operations by the 

  
 E-1

 
Borrower in, on or about any of its plants or warehouses; all field repair data, sales data and other information relating to sales or service of products now or hereafter manufactured on or
about any of its plants; and all accounting information pertaining to operations in, on or about any of its plants and all media in which or on which all of the information or knowledge or data or records relating to its plants and warehouses may be
recorded or stored and all computer programs used for the compilation or printout of such information, knowledge, records or data, and the Lender shall keep all such information, knowledge, records or data strictly confidential; 

(viii) all licenses and other agreements relating in whole or in part to any of the foregoing, including all rights to payments in respect
thereof; 
 (ix) all rights to sue for past, present or future infringements of any of the foregoing; 

(x) to the extent not included above, all general intangibles (as such term is defined in the UCC) of the Borrower representing the
foregoing; and 
 (xii) all proceeds of any and all of the foregoing. 
 Section 3. Reference to Separate Loan Agreement. This Agreement has been entered into by the Borrower and the Lender primarily for recording purposes as contemplated by the Loan Agreement,
dated as of the date hereof, between the Borrower, as debtor, and the Lender, as secured party. In the event of any inconsistency between any of the terms or provisions hereof and the terms and provisions of such Loan Agreement, the terms and
provisions of such Loan Agreement shall govern. 
 IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be executed and
delivered by their duly authorized officers as of the date first set forth above. 
  

			
	PONIARD PHARMACEUTICALS, INC.
		
	By:	 	 
		 	Name:
		 	Title:

 Accepted and acknowledged by: 
  

			
	BAY CITY CAPITAL FUND IV, L.P.
	
	 By: Bay City Capital Management IV LLC,
 its general partner

	
	By: Bay City Capital LLC, its manager
		
	By:	 	 
	 Name:
	 	
	 Title:
	 	 Managing Director

  
 E-2

 Schedule A 
 to Collateral Assignment of 
 Trademarks 

 

							
	 Trademarks
	  	Country	  	Serial No.	  	Registration No.
				
	 PONIARD
	  	US	  	77/926,443	  	
				
	 PONIARD
	  	EUROPE	  	5136247	  	5136247
				
	 PONIARD
	  	BULGARIA	  	87794	  	64215
				
	 PONIARD
	  	CANADA	  	1,305,719	  	
				
	 PONIARD
	  	CHINA	  	5420788	  	5420788
				
	 PONIARD
	  	JAPAN	  	2006-55411	  	5011442
				
	 PONIARD
	  	MEXICO	  	788572	  	953650
				
	 PONIARD
	  	ROMANIA	  	M2006-06634	  	078934
				
	 PONIARD
	  	RUSSIA	  	2006716360	  	334572
				
	 PONIARD
	  	UKRAINE	  	M200608493	  	83816
				
	 PONIARD
	  	US	  	78/941,640	  	3,247,488
				
	 PONIARD
	  	EUROPE	  	5646484	  	5646484
				
	 PONIARD
	  	CANADA	  	1,332,920	  	
				
	 PONIARD
	  	CHINA	  	5875890	  	5875890
				
	 PONIARD
	  	INDIA	  	1526598	  	
				
	 PONIARD
	  	JAPAN	  	20076424	  	5051753
				
	 PONIARD
	  	MEXICO	  	832693	  	1013834
				
	 PONIARD
	  	RUSSIA	  	2007701832	  	351832
				
	 PONIARD
	  	UKRAINE	  	M200701043	  	92279
				
	 P DESIGN
	  	EUROPE	  	5645965	  	5645965
				
	 P DESIGN
	  	CANADA	  	1,332,922	  	
				
	 P DESIGN
	  	CHINA	  	5875888	  	5875888

  
 E-3

							
	 P DESIGN
	  	INDIA	  	1526599	  	
				
	 P DESIGN
	  	JAPAN	  	20075966	  	5051751
				
	 P DESIGN
	  	MEXICO	  	832691	  	983191
				
	 P DESIGN
	  	RUSSIA	  	2007701837	  	342645
				
	 P DESIGN
	  	UKRAINE	  	M200701044	  	93525
				
	 P DESIGN
	  	US	  	78/941,637	  	3,247,487
				
	 P DESIGN
	  	CHINA	  	5875889	  	5875889
				
	 P DESIGN
	  	MEXICO	  	832692	  	1013833
				
	 P DESIGN
	  	RUSSIA	  	2007702270	  	350589
				
	 P PONIARD & DESIGN (LOGO)
	  	US	  	78/941,528	  	3,247,481
				
	 P DESIGN
	  	CROATIA	  	Z20070832A	  	Z20070832
				
	 P DESIGN
	  	SERBIA	  	Z9912007	  	55571
				
	 PONIARD
	  	CROATIA	  	Z20070831A	  	Z20070831
				
	 PONIARD
	  	SERBIA	  	Z9922007	  	55553

  
 E-4

 Exhibit C to 
 Loan and Security Agreement 
 PERFECTION CERTIFICATE 

In connection with a proposed transaction by and between Poniard Pharmaceuticals, Inc. (the “Borrower”) and Bay City Capital Fund IV,
L.P. (the “Lender”), the Borrower hereby certifies as follows: 
 Section 1. Legal Names, Organizations and
Jurisdictions of Organization. The exact legal name, the type of organization and the jurisdiction of organization or formation, as applicable, of the Borrower is as follows: 

 

									
	 Name
	  	Type of
Organization	 	  	Jurisdiction of
Organization/
Formation	 
	 Poniard Pharmaceuticals, Inc.
	  	 	Corporation	  	  	 	Delaware	  

 Section 2. Organizational and Federal Taxpayer Identification Numbers. The state issued
organizational identification number and federal taxpayer identification number of the Borrower is as follows: 
  

			
	 Organizational

Identification Number
	  	Federal Taxpayer
Identification Number
	 WA UBI# 600-542-428
	  	91-1261311

 Section 3. Chief Executive Offices and Mailing Addresses. The chief executive office address
and mailing address, including street address, city, county, state and ZIP code, of the Borrower is as follows: 
  

			
	 Chief Executive Office
	  	Mailing Address
	 750 Battery Street, Suite 330,

San Francisco, CA 94111
	  	same

 Section 4. Changes in Name, Jurisdiction of Organization or Corporate Structure. Except as
set forth below, the Borrower has not changed its legal name, jurisdiction of organization or corporate structure in any way (e.g., merger, consolidation, conversion, change in corporate form, change in jurisdiction of organization or
otherwise) within the past five years: 

			
	 Date of Change
	  	 Description of Change

	 June 16, 2006
	  	Name changed from NeoRx Corporation

 Section 5. Prior Addresses. Except as set forth below, the Borrower has not changed its chief
executive office within the past five years: 
  

	
	 Prior Address of Chief Executive Office

	 7000 Shoreline Court, Suite 270,

South San Francisco, CA 94080

 Section 6. Trade Names. Set forth below is each trade name or assumed name used by the
Borrower during the past five years or by which the Borrower has been known or has transacted any business during the past five years: 
  

			
	 Trade/Assumed Name

	 Poniard
	 	
	 Poniard Pharmaceuticals
	 	

 Section 7. Intellectual Property. Set forth below is a list of all trademarks, patents, and
applications therefor owned or used by the Borrower: 
 (a) Trademarks: 

 

							
	 Trademark
	  	 Country
	  	Application No.
and/or 
Registration No.	  	Application Filing
Date and/or
Registration Date
				
	 PONIARD
	  	US	  	77/926,443	  	
				
	 PONIARD
	  	EUROPE	  	5136247	  	3/26/2007
				
	 PONIARD
	  	BULGARIA	  	87794	  	3/25/2008
				
	 PONIARD
	  	CANADA	  	1,305,719	  	
				
	 PONIARD
	  	CHINA	  	5420788	  	9/7/2009
				
	 PONIARD
	  	JAPAN	  	2006-55411	  	12/15/2006
				
	 PONIARD
	  	MEXICO	  	788572	  	9/21/2006
				
	 PONIARD
	  	ROMANIA	  	M2006-06634	  	5/29/2007

							
	 Trademark
	  	 Country
	  	Application No.
and/or 
Registration No.	  	Application Filing
Date and/or
Registration Date
	 PONIARD
	  	RUSSIA	  	2006716360	  	9/24/2007
				
	 PONIARD
	  	UKRAINE	  	M200608493	  	10/25/2007
				
	 PONIARD
	  	US	  	78/941,640	  	5/29/2007
				
	 PONIARD
	  	EUROPE	  	5646484	  	1/17/2008
				
	 PONIARD
	  	CANADA	  	1,332,920	  	
				
	 PONIARD
	  	CHINA	  	5875890	  	3/28/2010
				
	 PONIARD
	  	INDIA	  	1526598	  	
				
	 PONIARD
	  	JAPAN	  	20076424	  	6/1/2007
				
	 PONIARD
	  	MEXICO	  	832693	  	11/27/2007
				
	 PONIARD
	  	RUSSIA	  	2007701832	  	6/4/2008
				
	 PONIARD
	  	UKRAINE	  	M200701043	  	5/26/2008
				
	 P DESIGN
	  	EUROPE	  	5645965	  	1/30/2008
				
	 P DESIGN
	  	CANADA	  	1,332,922	  	
				
	 P DESIGN
	  	CHINA	  	5875888	  	12/28/2009
				
	 P DESIGN
	  	INDIA	  	1526599	  	
				
	 P DESIGN
	  	JAPAN	  	20075966	  	6/1/2007
				
	 P DESIGN
	  	MEXICO	  	832691	  	4/30/2007
				
	 P DESIGN
	  	RUSSIA	  	2007701837	  	1/30/2008
				
	 P DESIGN
	  	UKRAINE	  	M200701044	  	6/25/2008
				
	 P DESIGN
	  	US	  	78/941,637	  	5/29/2007
				
	 P DESIGN
	  	CHINA	  	5875889	  	3/28/2010
				
	 P DESIGN
	  	MEXICO	  	832692	  	11/27/2007
				
	 P DESIGN
	  	RUSSIA	  	2007702270	  	5/20/2008

  

							
	 Trademark
	  	 Country
	  	Application No.
and/or 
Registration No.	  	Application Filing
Date and/or
Registration Date
	 P PONIARD & DESIGN (LOGO)
	  	US	  	78/941,528	  	5/29/2007
				
	 P DESIGN
	  	CROATIA	  	Z20070832A	  	2/8/2008
				
	 P DESIGN
	  	SERBIA	  	Z9912007	  	5/8/2007
				
	 PONIARD
	  	CROATIA	  	Z20070831A	  	2/8/2008
				
	 PONIARD
	  	SERBIA	  	Z9922007	  	5/8/2007

 (b) Patents: 
 The Following patents are owned by Poniard Pharmaceuticals, Inc: 
  

							
	 Patent
	  	 Country
	  	Application No.
or Registration
No. 
(as applicable)	  	Application Filing
Date or 
Registration
Date (as applicable)
	 USE OF PICOPLATIN TO TREAT SMALL CELL LUNG
 CANCER
	  	US	  	60/857,067	  	11/6/2006
				
	 USE OF PICOPLATIN TO TREAT SMALL CELL LUNG
 CANCER
	  	US	  	60/877,515	  	12/28/2006
				
	 USE OF PICOPLATIN TO TREAT SMALL CELL LUNG
 CANCER
	  	US	  	60/927,347	  	5/3/2007
				
	 USE OF PICOPLATIN TO TREAT SMALL CELL LUNG
 CANCER
	  	US	  	60/931,309	  	5/22/2007
				
	 USE OF PICOPLATIN TO TREAT SMALL CELL LUNG
 CANCER
	  	US	  	60/969,441	  	8/31/2007
				
	 USE OF PICOPLATIN TO TREAT SMALL CELL LUNG
 CANCER
	  	US	  	12/508,392	  	7/23/2009
				
	 A METHOD OF TREATMENT OF HORMONE-RESISTANT
 PROSTATE CANCER
	  	US	  	60/857,017	  	11/6/2006
				
	 A METHOD OF TREATMENT OF HORMONE-RESISTANT
 PROSTATE CANCER
	  	US	  	60/857,564	  	11/8/2006
				
	A METHOD OF	  	US	  	60/877,570	  	12/28/2006

  

							
	 Patent
	  	 Country
	  	Application No.
or Registration
No. 
(as applicable)	  	Application Filing
Date or 
Registration
Date (as applicable)
	TREATMENT OF HORMONE-RESISTANT PROSTATE CANCER	  		  		  	
				
	USE OF PICOPLATIN TO TREAT PROSTATE CANCER	  	US	  	60/889,179	  	2/9/2007
				
	USE OF PICOPLATIN TO TREAT PROSTATE CANCER	  	US	  	60/890,950	  	2/21/2007
				
	USE OF PICOPLATIN TO TREAT PROSTATE CANCER	  	US	  	60/931,609	  	5/24/2007
				
	USE OF PICOPLATIN TO TREAT PROSTATE CANCER	  	US	  	60/952,440	  	7/27/2007
				
	USE OF PICOPLATIN TO TREAT PROSTATE CANCER	  	US	  	11/935,979	  	11/6/2007
				
	A METHOD OF TREATMENT OF COLORECTAL CANCER	  	US	  	60/857,066	  	11/6/2006
				
	A METHOD OF TREATMENT OF COLORECTAL CANCER	  	US	  	60/857/725	  	11/8/2006
				
	USE OF PICOPLATIN TO TREAT COLORECTAL CANCER	  	US	  	60/889,191	  	2/9/2007
				
	USE OF PICOPLATIN TO TREAT COLORECTAL CANCER	  	US	  	60/931,589	  	5/24/2007
				
	USE OF PICOPLATIN TO TREAT COLORECTAL CANCER	  	US	  	60/683,852	  	10/30/2007
				
	USE OF PICOPLATIN TO TREAT COLORECTAL CANCER	  	US	  	12/367,394	  	2/6/2009
				
	USE OF PICOPLATIN TO TREAT COLORECTAL CANCER	  	US	  	12/465,563	  	5/13/2009
				
	USE OF PICOPLATIN TO TREAT COLORECTAL CANCER	  	US	  	12/508,372	  	7/23/2009

  

							
	 Patent
	  	 Country
	  	Application No.
or Registration
No. 
(as applicable)	  	Application Filing
Date or 
Registration
Date (as applicable)
	USE OF PICOPLATIN TO TREAT COLORECTAL CANCER	  	PCT	  	PCT/US2010/34593	  	5/12/2010
				
	ENCAPSULATED PICOPLATIN	  	US	  	60/889,201	  	2/9/2007
				
	ENCAPSULATED PICOPLATIN	  	US	  	60/889,675	  	2/13/2007
				
	ENCAPSULATED PICOPLATIN	  	US	  	60/984,156	  	10/31/2007
				
	ENCAPSULATED PICOPLATIN	  	US	  	60/989,020	  	11/19/2007
				
	ENCAPSULATED PICOPLATIN	  	PCT	  	PCT/US2008/001746	  	2/8/2009
				
	ENCAPSULATED PICOPLATIN	  	US	  	12/536,311	  	8/5/2009
				
	ENCAPSULATED PICOPLATIN	  	AU	  	2008214199	  	2/8/2008
				
	ENCAPSULATED PICOPLATIN	  	BR	  	PI 0806362-1	  	2/8/2008
				
	ENCAPSULATED PICOPLATIN	  	CA	  	2,677,639	  	2/8/2008
				
	ENCAPSULATED PICOPLATIN	  	CN	  	200880011347.9	  	2/8/2008
				
	ENCAPSULATED PICOPLATIN	  	EG	  	1200/2009	  	2/8/2008
				
	ENCAPSULATED PICOPLATIN	  	EP	  	08725387.8	  	2/8/2008
				
	ENCAPSULATED PICOPLATIN	  	HK	  	10102719.4	  	2/8/2008
				
	ENCAPSULATED PICOPLATIN	  	ID	  	W-00200902208	  	2/8/2008
				
	ENCAPSULATED PICOPLATIN	  	IL	  	200261	  	2/8/2008
				
	ENCAPSULATED PICOPLATIN	  	IN	  	5257/CHENP/2009	  	2/8/2008
				
	ENCAPSULATED PICOPLATIN	  	JP	  	2009-549126	  	2/8/2008
				
	ENCAPSULATED PICOPLATIN	  	KR	  	10-2009-7018781	  	2/8/2008
				
	ENCAPSULATED PICOPLATIN	  	MX	  	MX/s/2009/008487	  	2/8/2008
				
	ENCAPSULATED PICOPLATIN	  	PH	  	1-2009-501520	  	2/8/2008
				
	ENCAPSULATED PICOPLATIN	  	RU	  	2009133447	  	2/8/2008
				
	ENCAPSULATED PICOPLATIN	  	UA	  	200909261	  	2/8/2008
				
	ENCAPSULATED PICOPLATIN	  	VN	  	1-2009-01904	  	2/8/2008

  

							
	 Patent
	  	 Country
	  	Application No.
or Registration
No. 
(as applicable)	  	Application Filing
Date or 
Registration
Date (as applicable)
	STABILIZED PICOPLATIN ORAL DOSAGE FORM*	  	US	  	60/889,171	  	2/9/2007
				
	STABILIZED PICOPLATIN ORAL DOSAGE FORM*	  	US	  	60/889,681	  	2/13/2007
				
	STABILIZED PICOPLATIN ORAL DOSAGE FORM*	  	PCT	  	PCT/US2008/001752	  	2/8/2008
				
	STABILIZED PICOPLATIN ORAL DOSAGE FORM*	  	US	  	12/536,335	  	8/5/2009
				
	STABILIZED PICOPLATIN ORAL DOSAGE FORM*	  	AU	  	2008214202	  	2/8/2008
				
	STABILIZED PICOPLATIN ORAL DOSAGE FORM*	  	BR	  	0806418-0	  	2/8/2008
				
	STABILIZED PICOPLATIN ORAL DOSAGE FORM*	  	CA	  	2,677,640	  	2/8/2008
				
	STABILIZED PICOPLATIN ORAL DOSAGE FORM*	  	CN	  	200880011357.2	  	2/8/2008
				
	STABILIZED PICOPLATIN ORAL DOSAGE FORM*	  	EG	  	1201/2009	  	2/8/2008
				
	STABILIZED PICOPLATIN ORAL DOSAGE FORM*	  	EP	  	08725393.6	  	2/8/2008
				
	STABILIZED PICOPLATIN ORAL DOSAGE FORM*	  	HK	  	10106157.4	  	2/8/2008
				
	STABILIZED PICOPLATIN ORAL DOSAGE FORM*	  	ID	  	W-00200902207	  	2/8/2008
				
	STABILIZED PICOPLATIN ORAL DOSAGE FORM*	  	IL	  	200262	  	2/8/2008
				
	STABILIZED PICOPLATIN ORAL DOSAGE FORM*	  	IN	  	5256/CHENP/2009	  	2/8/2008
				
	STABILIZED PICOPLATIN ORAL DOSAGE FORM*	  	JP	  	2009-549128	  	2/8/2008

  

	*	co-owned with Genzyme Corporation 

  

							
				
	 STABILIZED PICOPLATIN ORAL DOSAGE FORM*
	  	KR	  	10-2009-7018780	  	2/8/208
				
	 STABILIZED PICOPLATIN ORAL DOSAGE FORM*
	  	MX	  	MX/a/2009/008488	  	2/8/2008
				
	 STABILIZED PICOPLATIN ORAL DOSAGE FORM*
	  	PH	  	1-2009-501521	  	2/8/2008
				
	 STABILIZED PICOPLATIN ORAL DOSAGE FORM*
	  	RU	  	2009133446	  	2/8/2008
				
	 STABILIZED PICOPLATIN ORAL DOSAGE FORM*
	  	UA	  	200909262	  	2/8/2008
				
	 STABILIZED PICOPLATIN ORAL DOSAGE FORM AND

PROCESS FOR PREPARING THE SAME*
	  	VN	  	1-2009-01903	  	2/8/2008
				
	 STABILIZED INTRAVENOUS DOSAGE FORM
	  	US	  	60/949,639	  	6/27/2007
				
	 ORAL FORMULATION FOR PICOPLATIN
	  	US	  	60/950,033	  	7/16/2007
				
	 ORAL FORMULATION FOR PICOPLATIN
	  	US	  	61/043,962	  	4/10/2008
				
	 ORAL FORMULATION FOR PICOPLATIN
	  	PCT	  	PCT/US2008/008669	  	7/16/2008
				
	 ORAL FORMULATION FOR PICOPLATIN
	  	US	  	12/669,274	  	1/15/2010
				
	 ORAL FORMULATION FOR PICOPLATIN
	  	CA	  	2,693,057	  	7/16/2008
				
	 ORAL FORMULATION FOR PICOPLATIN
	  	CN	  	200880103323.6	  	7/16/2008
				
	 ORAL FORMULATION FOR PICOPLATIN
	  	EP	  	08780206.2	  	7/16/2008
				
	 ORAL FORMULATION FOR PICOPLATIN
	  	HK	  	11101572.1	  	7/16/2008
				
	 ORAL FORMULATION FOR PICOPLATIN
	  	JP	  	2010-517010	  	7/16/2008
				
	 ORAL FORMULATION FOR PICOPLATIN
	  	TW	  	097127053	  	7/16/2008
				
	 USE OF PICOPLATIN AND BEVACIZUMAB TO TREAT

COLORECTAL CANCER
	  	US	  	61/027,387	  	2/8/2008
				
	 USE OF PICOPLATIN AND BEVACIZUMAB TO TREAT
	  	PCT	  	PCT/US2009/000770	  	2/6/2009

  

	*	co-owned with Genzyme Corporation 

  

							
	COLORECTAL CANCER	  		  		  	
				
	USE OF PICOPLATIN AND BEVACIZUMAB TO TREAT COLORECTAL CANCER	  	US	  	12/866,702	  	11/11/2010
				
	USE OF PICOPLATIN AND BEVACIZUMAB TO TREAT COLORECTAL CANCER	  	AU	  	2009210654	  	2/6/2009
				
	USE OF PICOPLATIN AND BEVACIZUMAB TO TREAT COLORECTAL CANCER	  	CA	  	2,715,348	  	2/6/2009
				
	USE OF PICOPLATIN AND BEVACIZUMAB TO TREAT COLORECTAL CANCER	  	CN	  	200980109758.6	  	2/6/2009
				
	USE OF PICOPLATIN AND BEVACIZUMAB TO TREAT COLORECTAL CANCER	  	EP	  	09708527.8	  	2/6/2009
				
	USE OF PICOPLATIN AND BEVACIZUMAB TO TREAT COLORECTAL CANCER	  	JP	  	2010-545883	  	2/6/2009
				
	USE OF PICOPLATIN AND BEVACIZUMAB TO TREAT COLORECTAL CANCER	  	US	  	61/027,382	  	2/8/2008
				
	USE OF PICOPLATIN AND BEVACIZUMAB TO TREAT COLORECTAL CANCER	  	PCT	  	PCT/
US2009/000773	  	2/6/2009
				
	USE OF PICOPLATIN AND BEVACIZUMAB TO TREAT COLORECTAL CANCER	  	US	  	12/866,706	  	11/15/2010
				
	USE OF PICOPLATIN AND BEVACIZUMAB TO TREAT COLORECTAL CANCER	  	AU	  	2009210656	  	2/6/2009
				
	USE OF PICOPLATIN AND BEVACIZUMAB TO TREAT COLORECTAL	  	CA	  	2,715,353	  	2/6/2009

  

							
	CANCER	  		  		  	
				
	USE OF PICOPLATIN AND BEVACIZUMAB TO TREAT COLORECTAL CANCER	  	CN	  	200980111015.2	  	2/6/2009
				
	USE OF PICOPLATIN AND BEVACIZUMAB TO TREAT COLORECTAL CANCER	  	EP	  	09708387.7	  	2/6/2009
				
	USE OF PICOPLATIN AND BEVACIZUMAB TO TREAT COLORECTAL CANCER	  	JP	  	2010-545885	  	2/6/2009
				
	USE OF PICOPLATIN AND BEVACIZUMAB TO TREAT COLORECTAL CANCER	  	US	  	61/027,360	  	2/8/2008
				
	PICOPLATIN AND AMRUBICIN TO TREAT LUNG CANCER	  	PCT	  	PCT/US2009/000750	  	2/6/2009
				
	PICOPLATIN AND AMRUBICIN TO TREAT LUNG CANCER	  	US	  	12/866,710	  	11/10/2010
				
	PICOPLATIN AND AMRUBICIN TO TREAT LUNG CANCER	  	AU	  	2009210734	  	2/6/2009
				
	PICOPLATIN AND AMRUBICIN TO TREAT LUNG CANCER	  	CA	  	2,715,329	  	2/6/2009
				
	PICOPLATIN AND AMRUBICIN TO TREAT LUNG CANCER	  	CN	  	200980110139.9	  	2/6/2009
				
	PICOPLATIN AND AMRUBICIN TO TREAT LUNG CANCER	  	EP	  	09708292.9	  	2/6/2009
				
	PICOPLATIN AND AMRUBICIN TO TREAT LUNG CANCER	  	JP	  	2010-545878	  	2/6/2009
				
	COMBINATION CHEMOTHERAPY COMPRISING STABILIZED INTRAVENOUS PICOPLATIN DOSAGE	  	US	  	61/027,388	  	2/8/2008

							
	FORM	  		  		  	
				
	COMBINATION CHEMOTHERAPY COMPRISING STABILIZED INTRAVENOUS PICOPLATIN DOSAGE FORM	  	US	  	61/055/071	  	5/21/2008
				
	STABILIZED PICOPLATIN DOSAGE FORM	  	PCT	  	PCT/US2008/08076	  	6/27/2008
				
	STABILIZED PICOPLATIN DOSAGE FORM	  	US	  	12/635,517	  	12/10/2009
				
	COMBINATION THERAPY FOR OVARIAN CANCER	  	US	  	12/635,534	  	12/10/2009
				
	COMBINATION THERAPY FOR OVARIAN CANCER	  	US	  	12/781,599	  	5/17/2010
				
	COMBINATION THERAPY FOR OVARIAN CANCER	  	PCT	  	PCT/US11/036855	  	5/17/2011
				
	STABILIZED PICOPLATIN DOSAGE FORM	  	AU	  	2008295576	  	6/27/2008
				
	STABILIZED PICOPLATIN DOSAGE FORM	  	BR	  	PI0811816-7	  	6/27/2008
				
	STABILIZED PICOPLATIN DOSAGE FORM	  	CA	  	2,691,115	  	6/27/2008
				
	STABILIZED PICOPLATIN DOSAGE FORM	  	CN	  	200880022248.0	  	6/27/2008
				
	STABILIZED PICOPLATIN DOSAGE FORM	  	EP	  	08828991.3	  	6/27/2008
				
	STABILIZED PICOPLATIN DOSAGE FORM	  	HK	  	10108170.3	  	6/27/2008
				
	STABILIZED PICOPLATIN DOSAGE FORM	  	ID	  	W-00201000277	  	6/27/2008
				
	STABILIZED PICOPLATIN DOSAGE FORM	  	IL	  		  	6/27/208
				
	STABILIZED PICOPLATIN DOSAGE FORM	  	IN	  	7725/CHENP/2009	  	6/27/2008
				
	STABILIZED PICOPLATIN DOSAGE FORM	  	JP	  	2010-514837	  	6/27/2008
				
	STABILIZED PICOPLATIN DOSAGE FORM	  	KR	  	10-2010-7001745	  	6/27/2008

							
				
	STABILIZED PICOPLATIN DOSAGE FORM	  	MX	  	MX/a/2009/013835	  	6/27/2008
				
	STABILIZED PICOPLATIN DOSAGE FORM	  	RU	  	2010102096	  	6/27/2008
				
	STABILIZED PICOPLATIN DOSAGE FORM	  	TW	  	097124033	  	6/28/2008
				
	STABILIZED PICOPLATIN DOSAGE FORM	  	UA	  	201000817	  	6/28/2008
				
	PICOPLATIN ORAL DOSAGE FORM HAVING HIGH BIOAVAILABILITY	  	US	  	61/169,679	  	4/15/2009
				
	PICOPLATIN ORAL DOSAGE FORM HAVING HIGH BIOAVAILABILITY	  	US	  	61/170,487	  	4/17/2009
				
	HIGH BIOVAILABILITY ORAL PICOPLATIN ANTI-CANCER THERAPY	  	PCT	  	PCT/US2010/00735	  	3/11/2010
				
	USE OF PICOPLATIN TO TREAT PROSTATE CANCER	  	US	  	61/177,567	  	5/12/2009
				
	USE OF PICOPLATIN TO TREAT PROSTATE CANCER	  	PCT	  	PCT/US2010/34591	  	5/12/2010
				
	USE OF PICOPLATING AND DOCETAXEL TO TREAT PROSTATE CANCER	  	US	  	61/177,571	  	5/12/2009
				
	IMPROVED SYNTHESIS OF PICOPLATIN	  	US	  	61/186,526	  	6/12/2009
				
	IMPROVED SYNTHESIS OF PICOPLATIN	  	PCT	  	PCT/US2010/38348	  	6/11/2010
				
	IMPROVED SYNTHESIS OF PICOPLATIN	  	TW	  	099119171	  	6/11/2010
				
	METHOD TO TREAT SMALL CELL LUNG CANCER	  	US	  	61/311,169	  	3/5/2010
				
	METHOD TO TREAT SMALL CELL LUNG CANCER	  	US	  	61/345,442	  	5/17/2010
				
	METHOD TO TREAT SMALL CELL LUNG CANCER	  	PCT	  	PCT/US2011/027264	  	3/4/2011

							
				
	METHOD TO TREAT SMALL CELL LUNG CANCER	  	TW	  	100107612	  	3/7/2011
				
	COMBINATION THERAPY FOR SMALL CELL LUNG CANCER	  	US	  	61/345,451	  	5/17/2010
				
	COMBINATION THERAPY FOR SMALL CELL LUNG CANCER	  	US	  	61/346,777	  	5/20/2010
				
	COMBINATION THERAPY FOR SMALL CELL LUNG CANCER	  	PCT	  	PCT/US2011/027268	  	3/4/2011
				
	COMBINATION THERAPY FOR SMALL CELL LUNG CANCER	  	TW	  	100107621	  	3/7/2011

 The Following patents are licensed by Poniard Pharmaceuticals, Inc: 

[***] [Portions of the next 11 pages have been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has
been requested with respect to the omitted portions.] 

 Section 8. Assigned Agreements. Set forth below is a list of all the agreements
to be assigned as collateral security by the Borrower under the agreements granting a security interest therein: 
  

			
	 Name of Agreement
	  	 Date and Parties

	Commercial Supply Agreement	  	Baxter Oncology GmbH and the Borrower, executed by the Borrower on November 22, 2008
		
	Commercial Picoplatin Active Pharmaceutical Ingredient Manufacturing Agreement	  	Dated March 24, 2008 between W.C. Heraeus GmbH and the Borrower
		
	Picoplatin Active Pharmaceutical Ingredient Manufacturing Agreement	  	Dated July 27, 2006 between W.C. Heraeus GmbH and the Borrower
		
	License Agreement	  	Dated April 2, 2004 and amended September 18, 2006 between AnorMed, Inc. and the Borrower

 Section 9. Authorization to File Financing Statements. The Borrower hereby
authorizes the Lender to file financing or continuation statements, and amendments thereto, in all jurisdictions and with all filing offices as the Lender may determine, in its sole discretion, are necessary or advisable to perfect the security
interest granted or to be granted to the Lender. Such financing statements may describe the collateral in the same manner as described in the agreement(s) granting a security interest or may contain an indication or description of collateral that
describes such property in any other manner as the Lender may determine, in its sole discretion, is necessary or advisable to ensure the perfection of the security interest in the collateral granted or to be granted to the Lender. 

IN WITNESS WHEREOF, the Borrower has caused this Perfection Certificate to be executed as of the
             day of             , 2011 by its officer thereunto duly authorized. 

 

					
	PONIARD PHARMACEUTICALS, INC.
		
	By:	 	 
		 	Name:	 	
		 	Title:	 	

 EXHIBIT D 
 SECURED NON-RECOURSE PROMISSORY NOTE 
  

			
	 $2,400,000
	  	            , 2011

 Seattle, Washington 
 FOR VALUE RECEIVED, Poniard Pharmaceuticals, Inc., a Washington corporation (the “Company”), promises to pay, without recourse, to the order of Bay City Capital Fund IV, L.P., a Delaware
limited partnership (the “Holder”), the principal sum of Two Million Four Hundred Thousand Dollars ($2,400,000), in lawful money of the United States of America in immediately available funds, with interest thereon (this
“Note”) (the outstanding principal amount hereof plus the accrued but unpaid interest hereon is referred to herein as the “Aggregate Amount”). Interest shall accrue on the unpaid principal of this Note at the rate
of Eighteen Percent (18.00%) per annum (based on a year of 365 days and for the actual number of calendar days elapsed), compounded annually. Interest shall commence on the date written above, continue to accrue on the outstanding principal
until paid in full in cash, and shall together with the outstanding principal be due and payable on one year from the issue date (the “Maturity Date”). This Note is issued pursuant to that certain Loan and Security Agreement dated
as of             , 2011 by and between the Company and the Holder (“Loan Agreement”). Capitalized terms used but not defined herein shall have the meanings given
them in the Loan Agreement. 
 The following is a statement of the rights of Holder and the conditions to which this Note is
subject, and to which Holder hereof, by the acceptance of this Note, agrees: 
 1. Prepayment. The Company may at any
time prior to the Maturity Date prepay the Aggregate Amount in whole or in part. 
 2. Security Interest; Non-recourse
Nature. This Note is secured by a security interest in certain Collateral (as defined in the Loan Agreement) as provided in the Loan Agreement. The Collateral shall be the sole recourse of the Holder with respect to this Note, and the liability
of the Company for the amounts due under this Note shall be limited to such Collateral, the distributions thereof and the proceeds of any assignments or sales thereof. Notwithstanding anything to the contrary set forth in this Note or in the Loan
Agreement, the Company shall have no liability under, or for the payment of, this Note other than the obligation to transfer the Collateral, or the proceeds thereof, to the Holder or to a third party on the exercise of the Holder’s rights under
the Loan Agreement. The Holder waives its right to enforce against the Company a judgment imposing liability on the Company for any failure to pay or deficiency in payment of the Aggregate Amount or any other amounts payable under this Note (other
than through delivery of the Collateral). Accordingly, neither the Company nor any of its officers, directors, shareholders, employees, members, agents or affiliates shall have any personal liability whatsoever under this Note and no property or
assets of the Company (other than the Collateral) or any other person shall be subject to levy, execution or other enforcement procedure for the satisfaction of the Holder’s remedies under this Note or pursuant to the Loan Agreement.

  
 1 

 3. Events of Default. If any of the following events shall occur (hereinafter
individually referred to as an “Event of Default”), Holder may declare the Aggregate Amount immediately due and payable, by notice in writing to the Company and may pursue any and all remedies available to it under applicable law or
pursuant to the Loan Agreement: 
 (a) failure to pay the Aggregate Amount in full on the Maturity Date;

 (b) any breach by the Company of any term, covenant, condition or agreement contained in any Transaction
Document; 
 (c) any representation or warranty made or deemed made by or on behalf of the Company in any
Transaction Document or any amendment or modification thereof or waiver thereunder, shall have been proven to be materially incorrect when made or deemed made; 
 (d) there occurs a Change in Control without Holder’s prior written consent; 
 (e) there occurs a default by the Company under any of the Assigned Agreements; 
 (f) any Transaction Document, as applicable, shall for any reason fail to create a valid and perfected first priority security interest in any Collateral purported to be covered thereby; 

(g) the institution by the Company of proceedings to be adjudicated as bankrupt or insolvent, or the consent by the
Company to institution of bankruptcy or insolvency proceedings against it, or the filing by the Company of a petition or answer or consent seeking reorganization or release under the federal Bankruptcy Act, or any other applicable federal or state
law, or the consent by it to the filing of any such petition or the appointment of a receiver, liquidator, assignee, trustee or other similar official of the Company, or of any substantial part of its property, or the making by it of an assignment
for the benefit of creditors, or the taking of corporate action by the Company in furtherance of any such action; or 
 (h) if within sixty (60) days after the commencement of an action against the Company (and service of process in connection therewith on the Company) seeking any bankruptcy, insolvency,
reorganization, liquidation, dissolution or similar relief under any present or future statute, law or regulation, such action shall not have been resolved in favor of the Company or all orders or proceedings thereunder affecting the operations or
the business of the Company stayed, or if the stay of any such order or proceeding shall thereafter be set aside, or if, within sixty (60) days after the appointment without the consent or acquiescence of the Company of any trustee, receiver or
liquidator of the Company, or of all or any substantial part of the properties of the Company, such appointment shall not have been vacated. 
 4. Default Rate. Upon the occurrence and during the continuation of an Event of Default, the rate of interest in effect during such time hereunder shall be increased by Two Percent (2.00%) per
annum. 

  
 2 

 5. Successors and Assigns. Subject to the restrictions on transfer described in
Section 7 below, the rights and obligations of the Company and the Holder shall be binding upon and benefit the successors, assigns, heirs, administrators and transferees of the parties. The Holder shall not be permitted to assign its rights or
delegate its obligations hereunder to any third party without the prior written consent of the Company; provided, however, the Holder shall be permitted to assign its rights and delegate its obligations under this Note to any entity
wholly-owned by the Holder without the consent of the Company. 
 6. Waiver and Amendment. Any provision of this Note may
be amended, waived or modified upon the written consent of the Company and the Holder. 
 7. Transfer of this Note. This
Note may not be transferred except with the prior written consent of the Company. 
 8. Notices. Any notice, request or
other communication required or permitted hereunder shall be in writing and shall be deemed to have been duly given if personally delivered, or mailed by registered or certified mail, postage prepaid, or by recognized overnight courier at the
respective addresses of the parties as set forth in the Loan Agreement or at such other address as the parties shall furnish to each other in writing. 
 9. Governing Law; Dispute Resolution. This Note and all actions arising out of or in connection with this Note shall be governed by and construed in accordance with the laws of the State of
Washington, without regard to the conflict of law provisions of the State of Washington or of any other state. 
 10.
Usury. In the event the Holder receives any sums under this Note which constitute interest in an amount in excess of that permitted by any applicable law, then, all such sums constituting interest in excess of that permitted to be paid under
applicable law shall, at the Holder’s option, either be credited to the payment of principal owing hereunder or returned to the Company. 
 11. Waivers. The Company and any endorsers of this Note, and each of them, hereby waive diligence, demand, presentment for payment, notice of non-payment, protest and notice of protest, and
specifically consent to and waive notice of any renewals or extensions of this Note, whether made to or in favor of the Company or any other person or persons. The Company and any endorsers of this Note expressly waive all right to the benefit of
any statute of limitations and any moratorium, reinstatement, marshaling, forbearance, extension, redemption, or appraisement now or hereafter provided by the Constitution and the laws of the United States and of any state thereof, as a defense to
any demand against the Company or any such endorsers, to the fullest extent permitted by law. 
 12. Headings. All
headings used herein are used for convenience only and shall not be used to construe or interpret this Note. 

STATUTORY NOTICE: ORAL AGREEMENTS OR ORAL COMMITMENTS TO LOAN MONEY, EXTEND CREDIT OR FORBEAR FROM 

  
 3 

 
ENFORCING REPAYMENT OF A DEBT ARE NOT ENFORCEABLE UNDER WASHINGTON LAW 
 IN WITNESS WHEREOF, the Company has caused this Note to be issued as of the date first written above. 

 

			
	 PONIARD PHARMACEUTICALS, INC.,
 a Washington corporation

		
	By:	 	 
	Name:	 	 
	Title:	 	 

  
 4 

 EXHIBIT E 
 Collateral Description 
 All right, title, interest, claims and demands of the
Borrower in and to the following property: 
 Trademarks: 
  

							
	 Trademark
	  	 Country
	  	 Application No.
and/or 
Registration No.
	  	 Application Filing
Date and/or
Registration Date

	 PONIARD
	  	US	  	77/926,443	  	
	 PONIARD
	  	EUROPE	  	5136247	  	3/26/2007
	 PONIARD
	  	BULGARIA	  	87794	  	3/25/2008
	 PONIARD
	  	CANADA	  	1,305,719	  	
	 PONIARD
	  	CHINA	  	5420788	  	9/7/2009
	 PONIARD
	  	JAPAN	  	2006-55411	  	12/15/2006
	 PONIARD
	  	MEXICO	  	788572	  	9/21/2006
	 PONIARD
	  	ROMANIA	  	M2006-06634	  	5/29/2007
	 PONIARD
	  	RUSSIA	  	2006716360	  	9/24/2007
	 PONIARD
	  	UKRAINE	  	M200608493	  	10/25/2007
	 PONIARD
	  	US	  	78/941,640	  	5/29/2007
	 PONIARD
	  	EUROPE	  	5646484	  	1/17/2008
	 PONIARD
	  	CANADA	  	1,332,920	  	
	 PONIARD
	  	CHINA	  	5875890	  	3/28/2010
	 PONIARD
	  	INDIA	  	1526598	  	
	 PONIARD
	  	JAPAN	  	20076424	  	6/1/2007
	 PONIARD
	  	MEXICO	  	832693	  	11/27/2007

							
	 Trademark
	  	 Country
	  	 Application No.
and/or 
Registration No.
	  	 Application Filing
Date and/or
Registration Date

	 PONIARD
	  	RUSSIA	  	2007701832	  	6/4/2008
	 PONIARD
	  	UKRAINE	  	M200701043	  	5/26/2008
	 P DESIGN
	  	EUROPE	  	5645965	  	1/30/2008
	 P DESIGN
	  	CANADA	  	1,332,922	  	
	 P DESIGN
	  	CHINA	  	5875888	  	12/28/2009
	 P DESIGN
	  	INDIA	  	1526599	  	
	 P DESIGN
	  	JAPAN	  	20075966	  	6/1/2007
	 P DESIGN
	  	MEXICO	  	832691	  	4/30/2007
	 P DESIGN
	  	RUSSIA	  	2007701837	  	1/30/2008
	 P DESIGN
	  	UKRAINE	  	M200701044	  	6/25/2008
	 P DESIGN
	  	US	  	78/941,637	  	5/29/2007
	 P DESIGN
	  	CHINA	  	5875889	  	3/28/2010
	 P DESIGN
	  	MEXICO	  	832692	  	11/27/2007
	 P DESIGN
	  	RUSSIA	  	2007702270	  	5/20/2008
	 P PONIARD & DESIGN (LOGO)
	  	US	  	78/941,528	  	5/29/2007
	 P DESIGN
	  	CROATIA	  	Z20070832A	  	2/8/2008
	 P DESIGN
	  	SERBIA	  	Z9912007	  	5/8/2007
	 PONIARD
	  	CROATIA	  	Z20070831A	  	2/8/2008
	 PONIARD
	  	SERBIA	  	Z9922007	  	5/8/2007

 Patents: 
  

									
	 Patent
	  	 Country
	  	 Application No.
or Registration
No.

(as applicable)
	  	 Application
Filing
Date or Registration
Date (as applicable)

	 USE OF PICOPLATIN TO TREAT SMALL CELL LUNG CANCER
	  	US	  	60/857,067	  	11/6/2006
	 USE OF PICOPLATIN TO TREAT SMALL CELL LUNG CANCER
	  	US	  	60/877,515	  	12/28/2006
	 USE OF PICOPLATIN TO TREAT SMALL CELL LUNG CANCER
	  	US	  	60/927,347	  	5/3/2007
	 USE OF PICOPLATIN TO TREAT SMALL CELL LUNG CANCER
	  	US	  	60/931,309	  	5/22/2007
	 USE OF PICOPLATIN TO TREAT SMALL CELL LUNG CANCER
	  	US	  	60/969,441	  	8/31/2007
	 USE OF PICOPLATIN TO TREAT SMALL CELL LUNG CANCER
	  	US	  	12/508,392	  	7/23/2009
	 A METHOD OF TREATMENT OF HORMONE-RESISTANT PROSTATE CANCER
	  	US	  	60/857,017	  	11/6/2006
	 A METHOD OF TREATMENT OF HORMONE-RESISTANT PROSTATE CANCER
	  	US	  	60/857,564	  	11/8/2006
	 A METHOD OF TREATMENT OF HORMONE-RESISTANT PROSTATE CANCER
	  	US	  	60/877,570	  	12/28/2006
	 USE OF PICOPLATIN TO TREAT PROSTATE CANCER
	  	US	  	60/889,179	  	2/9/2007
	 USE OF PICOPLATIN TO TREAT PROSTATE CANCER
	  	US	  	60/890,950	  	2/21/2007
	 USE OF PICOPLATIN TO TREAT PROSTATE CANCER
	  	US	  	60/931,609	  	5/24/2007
	 USE OF PICOPLATIN TO TREAT PROSTATE CANCER
	  	US	  	60/952,440	  	7/27/2007
	 USE OF PICOPLATIN TO TREAT PROSTATE CANCER
	  	US	  	11/935,979	  	11/6/2007

							
	 Patent
	  	 Country
	  	 Application No. or
Registration No.
(as applicable)
	  	 Application
Filing
Date or Registration
Date (as applicable)

	 A METHOD OF TREATMENT OF COLORECTAL CANCER
	  	US	  	60/857,066	  	11/6/2006
	 A METHOD OF TREATMENT OF COLORECTAL CANCER
	  	US	  	60/857/725	  	11/8/2006
	 USE OF PICOPLATIN TO TREAT COLORECTAL CANCER
	  	US	  	60/889,191	  	2/9/2007
	 USE OF PICOPLATIN TO TREAT COLORECTAL CANCER
	  	US	  	60/931,589	  	5/24/2007
	 USE OF PICOPLATIN TO TREAT COLORECTAL CANCER
	  	US	  	60/683,852	  	10/30/2007
	 USE OF PICOPLATIN TO TREAT COLORECTAL CANCER
	  	US	  	12/367,394	  	2/6/2009
	 USE OF PICOPLATIN TO TREAT COLORECTAL CANCER
	  	US	  	12/465,563	  	5/13/2009
	 USE OF PICOPLATIN TO TREAT COLORECTAL CANCER
	  	US	  	12/508,372	  	7/23/2009
	 USE OF PICOPLATIN TO TREAT COLORECTAL CANCER
	  	PCT	  	PCT/US2010/34593	  	5/12/2010
	 ENCAPSULATED PICOPLATIN
	  	US	  	60/889,201	  	2/9/2007
	 ENCAPSULATED PICOPLATIN
	  	US	  	60/889,675	  	2/13/2007
	 ENCAPSULATED PICOPLATIN
	  	US	  	60/984,156	  	10/31/2007
	 ENCAPSULATED PICOPLATIN
	  	US	  	60/989,020	  	11/19/2007
	 ENCAPSULATED PICOPLATIN
	  	PCT	  	PCT/US2008/001746	  	2/8/2009
	 ENCAPSULATED PICOPLATIN
	  	US	  	12/536,311	  	8/5/2009
	 ENCAPSULATED PICOPLATIN
	  	AU	  	2008214199	  	2/8/2008

							
	 Patent
	  	 Country
	  	
Application No.
or Registration
No.
(as applicable)
	  	 Application
Filing
Date or Registration
Date (as applicable)

	 ENCAPSULATED PICOPLATIN
	  	BR	  	PI 0806362-1	  	2/8/2008
	 ENCAPSULATED PICOPLATIN
	  	CA	  	2,677,639	  	2/8/2008
	 ENCAPSULATED PICOPLATIN
	  	CN	  	200880011347.9	  	2/8/2008
	 ENCAPSULATED PICOPLATIN
	  	EG	  	1200/2009	  	2/8/2008
	 ENCAPSULATED PICOPLATIN
	  	EP	  	08725387.8	  	2/8/2008
	 ENCAPSULATED PICOPLATIN
	  	HK	  	10102719.4	  	2/8/2008
	 ENCAPSULATED PICOPLATIN
	  	ID	  	W-00200902208	  	2/8/2008
	 ENCAPSULATED PICOPLATIN
	  	IL	  	200261	  	2/8/2008
	 ENCAPSULATED PICOPLATIN
	  	IN	  	5257/CHENP/2009	  	2/8/2008
	 ENCAPSULATED PICOPLATIN
	  	JP	  	2009-549126	  	2/8/2008
	 ENCAPSULATED PICOPLATIN
	  	KR	  	10-2009-7018781	  	2/8/2008
	 ENCAPSULATED PICOPLATIN
	  	MX	  	MX/s/2009/008487	  	2/8/2008
	 ENCAPSULATED PICOPLATIN
	  	PH	  	1-2009-501520	  	2/8/2008
	 ENCAPSULATED PICOPLATIN
	  	RU	  	2009133447	  	2/8/2008
	 ENCAPSULATED PICOPLATIN
	  	UA	  	200909261	  	2/8/2008
	 ENCAPSULATED PICOPLATIN
	  	VN	  	1-2009-01904	  	2/8/2008
	 STABILIZED PICOPLATIN ORAL DOSAGE FORM*
	  	US	  	60/889,171	  	2/9/2007
	 STABILIZED PICOPLATIN ORAL DOSAGE FORM*
	  	US	  	60/889,681	  	2/13/2007
	 STABILIZED PICOPLATIN ORAL DOSAGE FORM*
	  	PCT	  	PCT/US2008/001752	  	2/8/2008
	 STABILIZED PICOPLATIN ORAL DOSAGE FORM*
	  	US	  	12/536,335	  	8/5/2009

  

	*	co-owned with Genzyme Corporation 

							
	 Patent
	  	 Country
	  	
Application No.
or Registration
No.
(as applicable)
	  	 Application
Filing
Date or Registration
Date (as applicable)

	 STABILIZED PICOPLATIN ORAL DOSAGE FORM*
	  	AU	  	2008214202	  	2/8/2008
	 STABILIZED PICOPLATIN ORAL DOSAGE FORM*
	  	BR	  	0806418-0	  	2/8/2008
	 STABILIZED PICOPLATIN ORAL DOSAGE FORM*
	  	CA	  	2,677,640	  	2/8/2008
	 STABILIZED PICOPLATIN ORAL DOSAGE FORM*
	  	CN	  	200880011357.2	  	2/8/2008
	 STABILIZED PICOPLATIN ORAL DOSAGE FORM*
	  	EG	  	1201/2009	  	2/8/2008
	 STABILIZED PICOPLATIN ORAL DOSAGE FORM*
	  	EP	  	08725393.6	  	2/8/2008
	 STABILIZED PICOPLATIN ORAL DOSAGE FORM*
	  	HK	  	10106157.4	  	2/8/2008
	 STABILIZED PICOPLATIN ORAL DOSAGE FORM*
	  	ID	  	W-00200902207	  	2/8/2008
	 STABILIZED PICOPLATIN ORAL DOSAGE FORM*
	  	IL	  	200262	  	2/8/2008
	 STABILIZED PICOPLATIN ORAL DOSAGE FORM*
	  	IN	  	5256/CHENP/2009	  	2/8/2008
	 STABILIZED PICOPLATIN ORAL DOSAGE FORM*
	  	JP	  	2009-549128	  	2/8/2008
	 STABILIZED PICOPLATIN ORAL DOSAGE FORM*
	  	KR	  	10-2009-7018780	  	2/8/2008
	 STABILIZED PICOPLATIN ORAL DOSAGE FORM*
	  	MX	  	MX/a/2009/008488	  	2/8/2008
	 STABILIZED PICOPLATIN ORAL DOSAGE FORM*
	  	PH	  	1-2009-501521	  	2/8/2008
	 STABILIZED PICOPLATIN ORAL DOSAGE FORM*
	  	RU	  	2009133446	  	2/8/2008

  
  *
co-owned with Genzyme Corporation 

							
	 Patent
	  	 Country
	  	
Application No.
or Registration
No.
(as applicable)
	  	 Application
Filing
Date or Registration
Date (as applicable)

	 STABILIZED PICOPLATIN ORAL DOSAGE FORM*
	  	UA	  	200909262	  	2/8/2008
	 STABILIZED PICOPLATIN ORAL DOSAGE FORM AND PROCESS FOR PREPARING THE SAME*
	  	VN	  	1-2009-01903	  	2/8/2008
	 STABILIZED INTRAVENOUS DOSAGE FORM
	  	US	  	60/949,639	  	6/27/2007
	 ORAL FORMULATION FOR PICOPLATIN
	  	US	  	60/950,033	  	7/16/2007
	 ORAL FORMULATION FOR PICOPLATIN
	  	US	  	61/043,962	  	4/10/2008
	 ORAL FORMULATION FOR PICOPLATIN
	  	PCT	  	PCT/US2008/008669	  	7/16/2008
	 ORAL FORMULATION FOR PICOPLATIN
	  	US	  	12/669,274	  	1/15/2010
	 ORAL FORMULATION FOR PICOPLATIN
	  	CA	  	2,693,057	  	7/16/2008
	 ORAL FORMULATION FOR PICOPLATIN
	  	CN	  	200880103323.6	  	7/16/2008
	 ORAL FORMULATION FOR PICOPLATIN
	  	EP	  	08780206.2	  	7/16/2008
	 ORAL FORMULATION FOR PICOPLATIN
	  	HK	  	11101572.1	  	7/16/2008
	 ORAL FORMULATION FOR PICOPLATIN
	  	JP	  	2010-517010	  	7/16/2008
	 ORAL FORMULATION FOR PICOPLATIN
	  	TW	  	097127053	  	7/16/2008
	 USE OF PICOPLATIN AND BEVACIZUMAB TO TREAT COLORECTAL CANCER
	  	US	  	61/027,387	  	2/8/2008
	 USE OF PICOPLATIN AND BEVACIZUMAB TO TREAT COLORECTAL CANCER
	  	PCT	  	PCT/US2009/000770	  	2/6/2009
	 USE OF PICOPLATIN AND BEVACIZUMAB TO TREAT COLORECTAL CANCER
	  	US	  	12/866,702	  	11/11/2010

  
 *
co-owned with Genzyme Corporation 

							
	 Patent
	  	 Country
	  	
Application No.
or Registration
No.
(as applicable)
	  	 Application
Filing
Date or Registration
Date (as applicable)

	 USE OF PICOPLATIN AND BEVACIZUMAB TO TREAT COLORECTAL CANCER
	  	AU	  	2009210654	  	2/6/2009
	 USE OF PICOPLATIN AND BEVACIZUMAB TO TREAT COLORECTAL CANCER
	  	CA	  	2,715,348	  	2/6/2009
	 USE OF PICOPLATIN AND BEVACIZUMAB TO TREAT COLORECTAL CANCER
	  	CN	  	200980109758.6	  	2/6/2009
	 USE OF PICOPLATIN AND BEVACIZUMAB TO TREAT COLORECTAL CANCER
	  	EP	  	09708527.8	  	2/6/2009
	 USE OF PICOPLATIN AND BEVACIZUMAB TO TREAT COLORECTAL CANCER
	  	JP	  	2010-545883	  	2/6/2009
	 USE OF PICOPLATIN AND BEVACIZUMAB TO TREAT COLORECTAL CANCER
	  	US	  	61/027,382	  	2/8/2008
	 USE OF PICOPLATIN AND BEVACIZUMAB TO TREAT COLORECTAL CANCER
	  	PCT	  	PCT/
US2009/000773	  	2/6/2009
	 USE OF PICOPLATIN AND BEVACIZUMAB TO TREAT COLORECTAL CANCER
	  	US	  	12/866,706	  	11/15/2010
	 USE OF PICOPLATIN AND BEVACIZUMAB TO TREAT COLORECTAL CANCER
	  	AU	  	2009210656	  	2/6/2009
	 USE OF PICOPLATIN AND BEVACIZUMAB TO TREAT COLORECTAL CANCER
	  	CA	  	2,715,353	  	2/6/2009

							
	 Patent
	  	 Country
	  	
Application No.
or Registration
No.
(as applicable)
	  	 Application
Filing
Date or Registration
Date (as applicable)

	 USE OF PICOPLATIN AND BEVACIZUMAB TO TREAT COLORECTAL CANCER
	  	CN	  	200980111015.2	  	2/6/2009
	 USE OF PICOPLATIN AND BEVACIZUMAB TO TREAT COLORECTAL CANCER
	  	EP	  	09708387.7	  	2/6/2009
	 USE OF PICOPLATIN AND BEVACIZUMAB TO TREAT COLORECTAL CANCER
	  	JP	  	2010-545885	  	2/6/2009
	 USE OF PICOPLATIN AND BEVACIZUMAB TO TREAT COLORECTAL CANCER
	  	US	  	61/027,360	  	2/8/2008
	 PICOPLATIN AND AMRUBICIN TO TREAT LUNG CANCER
	  	PCT	  	PCT/
US2009/000750	  	2/6/2009
	 PICOPLATIN AND AMRUBICIN TO TREAT LUNG CANCER
	  	US	  	12/866,710	  	11/10/2010
	 PICOPLATIN AND AMRUBICIN TO TREAT LUNG CANCER
	  	AU	  	2009210734	  	2/6/2009
	 PICOPLATIN AND AMRUBICIN TO TREAT LUNG CANCER
	  	CA	  	2,715,329	  	2/6/2009
	 PICOPLATIN AND AMRUBICIN TO TREAT LUNG CANCER
	  	CN	  	200980110139.9	  	2/6/2009
	 PICOPLATIN AND AMRUBICIN TO TREAT LUNG CANCER
	  	EP	  	09708292.9	  	2/6/2009
	 PICOPLATIN AND AMRUBICIN TO TREAT LUNG CANCER
	  	JP	  	2010-545878	  	2/6/2009

							
	 Patent
	  	 Country
	  	
Application No.
or Registration
No.
(as applicable)
	  	 Application
Filing
Date or Registration
Date (as applicable)

	 COMBINATION CHEMOTHERAPY COMPRISING STABILIZED INTRAVENOUS PICOPLATIN DOSAGE FORM
	  	US	  	61/027,388	  	2/8/2008
	 COMBINATION CHEMOTHERAPY COMPRISING STABILIZED INTRAVENOUS PICOPLATIN DOSAGE FORM
	  	US	  	61/055/071	  	5/21/2008
	 STABILIZED PICOPLATIN DOSAGE FORM
	  	PCT	  	PCT/
US2008/08076	  	6/27/2008
	 STABILIZED PICOPLATIN DOSAGE FORM
	  	US	  	12/635,517	  	12/10/2009
	 COMBINATION THERAPY FOR OVARIAN CANCER
	  	US	  	12/635,534	  	12/10/2009
	 COMBINATION THERAPY FOR OVARIAN CANCER
	  	US	  	12/781,599	  	5/17/2010
	 COMBINATION THERAPY FOR OVARIAN CANCER
	  	PCT	  	PCT/
US11/036855	  	5/17/2011
	 STABILIZED PICOPLATIN DOSAGE FORM
	  	AU	  	2008295576	  	6/27/2008
	 STABILIZED PICOPLATIN DOSAGE FORM
	  	BR	  	PI0811816-7	  	6/27/2008
	 STABILIZED PICOPLATIN DOSAGE FORM
	  	CA	  	2,691,115	  	6/27/2008
	 STABILIZED PICOPLATIN DOSAGE FORM
	  	CN	  	200880022248.0	  	6/27/2008
	 STABILIZED PICOPLATIN DOSAGE FORM
	  	EP	  	08828991.3	  	6/27/2008
	 STABILIZED PICOPLATIN DOSAGE FORM
	  	HK	  	10108170.3	  	6/27/2008
	 STABILIZED PICOPLATIN DOSAGE FORM
	  	ID	  	W-00201000277	  	6/27/2008

							
	 Patent
	  	 Country
	  	
Application No.
or Registration
No.
(as applicable)
	  	 Application
Filing
Date or Registration
Date (as applicable)

	 STABILIZED PICOPLATIN DOSAGE FORM
	  	IL	  		  	6/27/2008
	 STABILIZED PICOPLATIN DOSAGE FORM
	  	IN	  	7725/CHENP/
2009	  	6/27/2008
	 STABILIZED PICOPLATIN DOSAGE FORM
	  	JP	  	2010-514837	  	6/27/2008
	 STABILIZED PICOPLATIN DOSAGE FORM
	  	KR	  	10-2010-7001745	  	6/27/2008
	 STABILIZED PICOPLATIN DOSAGE FORM
	  	MX	  	MX/a/
2009/013835	  	6/27/2008
	 STABILIZED PICOPLATIN DOSAGE FORM
	  	RU	  	2010102096	  	6/27/2008
	 STABILIZED PICOPLATIN DOSAGE FORM
	  	TW	  	097124033	  	6/28/2008
	 STABILIZED PICOPLATIN DOSAGE FORM
	  	UA	  	201000817	  	6/28/2008
	 PICOPLATIN ORAL DOSAGE FORM HAVING HIGH BIOAVAILABILITY
	  	US	  	61/169,679	  	4/15/2009
	 PICOPLATIN ORAL DOSAGE FORM HAVING HIGH BIOAVAILABILITY
	  	US	  	61/170,487	  	4/17/2009
	 HIGH BIOVAILABILITY ORAL PICOPLATIN ANTI-CANCER THERAPY
	  	PCT	  	PCT/
US2010/00735	  	3/11/2010
	 USE OF PICOPLATIN TO TREAT PROSTATE CANCER
	  	US	  	61/177,567	  	5/12/2009
	 USE OF PICOPLATIN TO TREAT PROSTATE CANCER
	  	PCT	  	PCT/
US2010/34591	  	5/12/2010
	 USE OF PICOPLATING AND DOCETAXEL TO TREAT PROSTATE CANCER
	  	US	  	61/177,571	  	5/12/2009
	 IMPROVED SYNTHESIS OF PICOPLATIN
	  	US	  	61/186,526	  	6/12/2009

							
	 Patent
	  	 Country
	  	
Application No.
or Registration
No.
(as applicable)
	  	 Application
Filing
Date or Registration
Date (as applicable)

	 IMPROVED SYNTHESIS OF PICOPLATIN
	  	PCT	  	PCT/
US2010/38348	  	6/11/2010
	 IMPROVED SYNTHESIS OF PICOPLATIN
	  	TW	  	099119171	  	6/11/2010
	 METHOD TO TREAT SMALL CELL LUNG CANCER
	  	US	  	61/311,169	  	3/5/2010
	 METHOD TO TREAT SMALL CELL LUNG CANCER
	  	US	  	61/345,442	  	5/17/2010
	 METHOD TO TREAT SMALL CELL LUNG CANCER
	  	PCT	  	PCT/
US2011/027264	  	3/4/2011
	 METHOD TO TREAT SMALL CELL LUNG CANCER
	  	TW	  	100107612	  	3/7/2011
	 COMBINATION THERAPY FOR SMALL CELL LUNG CANCER
	  	US	  	61/345,451	  	5/17/2010
	 COMBINATION THERAPY FOR SMALL CELL LUNG CANCER
	  	US	  	61/346,777	  	5/20/2010
	 COMBINATION THERAPY FOR SMALL CELL LUNG CANCER
	  	PCT	  	PCT/
US2011/027268	  	3/4/2011
	 COMBINATION THERAPY FOR SMALL CELL LUNG CANCER
	  	TW	  	100107621	  	3/7/2011

 EXHIBIT B 

Secured Non-Recourse Promissory Note 
 [See Exhibit D to the Loan and Security Agreement]

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00192-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00192-of-00352.parquet"}]]